<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id><journal-id journal-id-type="iso-abbrev">Proc Natl Acad Sci U S A</journal-id><journal-id journal-id-type="pmc-domain-id">2</journal-id><journal-id journal-id-type="pmc-domain">pnas</journal-id><journal-id journal-id-type="publisher-id">PNAS</journal-id><journal-title-group><journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title></journal-title-group><issn pub-type="ppub">0027-8424</issn><issn pub-type="epub">1091-6490</issn><publisher><publisher-name>National Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12773717</article-id><article-id pub-id-type="pmcid-ver">PMC12773717.1</article-id><article-id pub-id-type="pmcaid">12773717</article-id><article-id pub-id-type="pmcaiid">12773717</article-id><article-id pub-id-type="pmid">41481470</article-id><article-id pub-id-type="doi">10.1073/pnas.2525144122</article-id><article-id pub-id-type="publisher-id">202525144</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="type"><compound-subject><compound-subject-part content-type="code">research-article</compound-subject-part><compound-subject-part content-type="label">Research Article</compound-subject-part></compound-subject></subj-group><subj-group subj-group-type="topic"><compound-subject><compound-subject-part content-type="code">cell-bio</compound-subject-part><compound-subject-part content-type="label">Cell Biology</compound-subject-part></compound-subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>409</subject></subj-group><subj-group subj-group-type="heading"><subject>Biological Sciences</subject><subj-group><subject>Cell Biology</subject></subj-group></subj-group></article-categories><title-group><article-title>CHAMP1 complex promotes heterochromatin assembly and reduces replication stress</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Li</surname><given-names initials="F">Feng</given-names></name><email>feng_li@dfci.harvard.edu</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="cor1" ref-type="corresp">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Elbakry</surname><given-names initials="A">Amira</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="FY">Felix Y.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="T">Tianpeng</given-names></name><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ravindranathan</surname><given-names initials="R">Ramya</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7880-8593</contrib-id></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nguyen</surname><given-names initials="H">Huy</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Syed</surname><given-names initials="A">Aleem</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7942-3900</contrib-id></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sun</surname><given-names initials="L">Lifang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mukkavalli</surname><given-names initials="S">Sirisha</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Greenberg</surname><given-names initials="RA">Roger A.</given-names></name><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>D&#8217;Andrea</surname><given-names initials="AD">Alan D.</given-names></name><email>alan_dandrea@dfci.harvard.edu</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="cor1" ref-type="corresp">
<sup>1</sup>
</xref><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6168-6294</contrib-id></contrib><aff id="aff1"><sup>a</sup><institution>Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School</institution>, <city>Boston</city>, <state>MA</state>
<postal-code>02215</postal-code></aff><aff id="aff2"><sup>b</sup><institution>Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-Sen University</institution>, <city>Guangzhou</city>
<postal-code>510060</postal-code>, <country>China</country></aff><aff id="aff3"><sup>c</sup><institution>Department of Cancer Biology, Penn Center for Genome Integrity, Basser Center for BRCA, Perelman School of Medicine, University of Pennsylvania</institution>, <city>Philadelphia</city>, <state>PA</state>
<postal-code>19104</postal-code></aff><aff id="aff4"><sup>d</sup><institution>Department of Radiation Oncology, University of Virginia School of Medicine</institution>, <city>Charlottesville</city>, <state>VA</state>
<postal-code>22908</postal-code></aff></contrib-group><author-notes><corresp id="cor1"><sup>1</sup>To whom correspondence may be addressed. Email: <email>feng_li@dfci.harvard.edu</email> or <email>alan_dandrea@dfci.harvard.edu</email>.</corresp><fn id="fn1" fn-type="edited-by"><p>Contributed by Alan D&#8217;Andrea; received September 9, 2025; accepted November 18, 2025; reviewed by Christopher J. Bakkenist and Tony T. Huang</p></fn></author-notes><pub-date publication-format="electronic" date-type="pub"><day>2</day><month>1</month><year>2026</year></pub-date><pub-date publication-format="print" date-type="pub"><day>6</day><month>1</month><year>2026</year></pub-date><volume>123</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">504297</issue-id><elocation-id>e2525144122</elocation-id><history><date date-type="received"><day>09</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>11</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>07</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-07 10:25:13.903"><day>07</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2026 the Author(s). Published by PNAS.</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This open access article is distributed under <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pnas.202525144.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="pnas.202525144.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" xlink:title="research-article" journal-id="bioRxiv" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC12340823"><article-title>
CHAMP1 Complex Promotes Heterochromatin Assembly and Reduces Replication Stress
</article-title><date><day>5</day><month>8</month><year>2025</year></date><elocation-id>2025.08.05.667964</elocation-id><source>bioRxiv</source><pub-id pub-id-type="pmcid">PMC12340823</pub-id><pub-id pub-id-type="pmid">40799599</pub-id></related-article><abstract abstract-type="executive-summary"><title>Significance</title><p>Replication stress (RS) is a major driver of genome instability in cancer. We discovered that the CHAMP1 complex, a set of proteins that assembles heterochromatin, plays a critical role in relieving RS. By depositing repressive histone marks, the complex stabilizes replication forks and prevents their degradation. Disruption of CHAMP1 complex creates unique vulnerabilities in cancer cells, including those cells with the (ALT) mechanism of telomere maintenance or with CCNE1 amplification. Our findings reveal a mechanism by which heterochromatin structure can safeguard DNA replication and highlight CHAMP1 as a potential therapeutic target for tumors with high levels of RS.</p></abstract><abstract><p>Replication stress (RS) is a major driver of genomic instability and a hallmark of cancer cells. Although dynamic heterochromatin remodeling has been implicated in RS response, the precise mechanisms remain unclear. The CHAMP1 complex, composed of CHAMP1, POGZ, HP1&#945;, and the H3K9 methyltransferase SETDB1, is known to regulate heterochromatin assembly at multiple genomic sites. Interestingly, upon RS, the CHAMP1 complex is transiently recruited to stalled replication forks, where it facilitates H3K9me3 deposition and establishes a repressive chromatin environment. The complex is required for stabilization of replication forks, and it shields forks from MRE11-mediated degradation. The complex also reduces RS at specific chromosomal sites, such as the heterochromatin-rich telomeric sites in tumor cells which use the ALT pathway of telomere maintenance. Loss of the CHAMP1 complex results in increased micronuclei formation and heightened sensitivity to RS. Loss of the complex also leads to a compensatory increase in other pathways which reduce RS, such as the FA pathway and the ATR/CHK1 pathway. Notably, CHAMP1 deficiency induces synthetic lethality with FANCM inhibition in ALT-positive tumor cells, and the CHAMP1 complex is essential for the survival of CCNE1-amplified ovarian cancers. These findings uncover a heterochromatin-based mechanism of replication fork stabilization and suggest that CHAMP1 may represent a candidate therapeutic vulnerability in cancers with elevated RS.</p></abstract><kwd-group><kwd>CHAMP1</kwd><kwd>POGZ</kwd><kwd>SETDB1</kwd><kwd>H3K9me3</kwd><kwd>replication stress</kwd></kwd-group><funding-group specific-use="FundRef"><award-group award-type="grant"><funding-source id="sp1"><institution-wrap><institution>HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)</institution><institution-id institution-id-type="FundRef">100000050</institution-id></institution-wrap></funding-source><award-id rid="sp1">R01HL052725</award-id><principal-award-recipient>Alan D. D&#8217;Andrea</principal-award-recipient></award-group><award-group award-type="grant"><funding-source id="sp2"><institution-wrap><institution>Breast Cancer Research Foundation (BCRF)</institution><institution-id institution-id-type="FundRef">100001006</institution-id></institution-wrap></funding-source><award-id rid="sp2">BCRF-24-033</award-id><principal-award-recipient>Alan D. D&#8217;Andrea</principal-award-recipient></award-group><award-group award-type="grant"><funding-source id="sp3"><institution-wrap><institution>David Liposarcoma Research Initiative</institution></institution-wrap></funding-source><award-id rid="sp3">G404-2021</award-id><principal-award-recipient>Alan D. D&#8217;Andrea</principal-award-recipient></award-group></funding-group><counts><page-count count="11"/><word-count count="6984"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p content-type="flushleft">Genomic instability is a hallmark of cancer and is often driven by replication stress (RS)&#8212;a condition in which replication forks stall or collapse due to obstacles during DNA synthesis. RS is often triggered by a variety of oncogenic events, including overexpression of MYC or Cyclin E, loss of the p53-mediated G1/S checkpoint, or deficiencies in DNA repair pathways (<xref rid="r1" ref-type="bibr">1</xref><xref rid="r2" ref-type="bibr"/><xref rid="r3" ref-type="bibr"/>&#8211;<xref rid="r4" ref-type="bibr">4</xref>). These RS events result in the cellular accumulation of free single-strand DNA, triggering activation of the ATR/CHK1 pathway, which slows cell cycle progression and alleviates RS (<xref rid="r5" ref-type="bibr">5</xref>).</p><p>RS can also be localized to specific regions of the genome and is amplified in specific cellular contexts. For instance, in about 10 to 15% human cancers, telomere length is maintained via the alternative lengthening of telomere (ALT) mechanism (<xref rid="r6" ref-type="bibr">6</xref>, <xref rid="r7" ref-type="bibr">7</xref>) which bypasses the need for telomerase-mediated telomere lengthening. ALT-positive tumor cells are characterized by high local RS at telomeres and rely heavily on homology-directed repair (HDR) and DNA damage response pathways, including the ATR/CHK1 pathway (<xref rid="r8" ref-type="bibr">8</xref>) and the Fanconi anemia (FA) pathway (<xref rid="r9" ref-type="bibr">9</xref>). Notably, ALT tumor cells are highly sensitive to inhibitors of the FANCM translocase enzyme (<xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r12" ref-type="bibr">12</xref>).</p><p>Recent studies have implicated the CHAMP1 protein complex in regulating chromatin assembly at ALT telomeres (<xref rid="r13" ref-type="bibr">13</xref>). This complex recruits the SETDB1 methyltransferase to regions undergoing heterochromatin assembly, such as telomeres and centromeres and increases the local level of H3K9me3 at these sites (<xref rid="r13" ref-type="bibr">13</xref>). This process is required for the clustering of telomeres, known to promote homology-directed DNA repair (<xref rid="r14" ref-type="bibr">14</xref>) and is critical for the recruitment of homologous recombination proteins to these sites and the local repair of DNA double-strand breaks (DSBs) (<xref rid="r13" ref-type="bibr">13</xref>). The CHAMP1 complex also promotes homology-directed repair at other DSBs in euchromatin, by binding to REV7 and reducing the level of the SHLD protein complex (<xref rid="r15" ref-type="bibr">15</xref>, <xref rid="r16" ref-type="bibr">16</xref>). The SHLD complex inhibits DSB end resection, thereby suppressing homologous recombination (<xref rid="r17" ref-type="bibr">17</xref><xref rid="r18" ref-type="bibr"/><xref rid="r19" ref-type="bibr"/><xref rid="r20" ref-type="bibr"/>&#8211;<xref rid="r21" ref-type="bibr">21</xref>).</p><p>Beyond their roles in chromatin regulation and DNA repair, CHAMP1 and POGZ are clinically relevant genes. De novo heterozygous mutations in the <italic toggle="yes">CHAMP1</italic> gene cause CHAMP1 syndrome, a neurodevelopmental disorder featuring intellectual disability, delayed speech development, behavioral abnormalities, and distinctive facial dysmorphism (<xref rid="r22" ref-type="bibr">22</xref><xref rid="r23" ref-type="bibr"/><xref rid="r24" ref-type="bibr"/><xref rid="r25" ref-type="bibr"/>&#8211;<xref rid="r26" ref-type="bibr">26</xref>). A recent study indicates that patients with CHAMP1 syndrome develop acute myeloid leukemia, suggesting a broader role of the CHAMP1 complex in reducing RS and maintaining the genomic stability of hematopoietic stem and progenitor cells (<xref rid="r22" ref-type="bibr">22</xref>). Interestingly, de novo heterozygous mutations in <italic toggle="yes">POGZ</italic> lead to White&#8211;Sutton syndrome (WSS), a rare neurodevelopmental syndrome that shares many clinical features with CHAMP1 syndrome (<xref rid="r27" ref-type="bibr">27</xref><xref rid="r28" ref-type="bibr"/><xref rid="r29" ref-type="bibr"/><xref rid="r30" ref-type="bibr"/><xref rid="r31" ref-type="bibr"/><xref rid="r32" ref-type="bibr"/><xref rid="r33" ref-type="bibr"/><xref rid="r34" ref-type="bibr"/>&#8211;<xref rid="r35" ref-type="bibr">35</xref>). These human syndromes underscore the physiological importance of CHAMP1/POGZ in regulating chromatin and maintaining genome integrity. How this complex protects against RS in proliferating cells remains poorly understood.</p><p>Here, we show that the CHAMP1 complex plays a critical role in reducing RS in human cancer cells. Loss of the CHAMP1 complex sensitizes cells to RS-inducing agents such as hydroxyurea (HU) and induces compensatory mechanisms, including the ATR/CHK1 pathway and the Fanconi Anemia pathway. Loss of the CHAMP1 complex results in recruitment of proteins involved in the FA pathway, including the ATPase, FANCM, to telomeres. Together, our findings reveal a function of the CHAMP1 complex in reducing RS and demonstrate that the CHAMP1 complex is essential in cancer cells exhibiting high RS.</p><sec sec-type="results" id="s1"><title>Results</title><sec id="s2"><title>CHAMP1 Complex Relieves RS and Prevents Micronuclei Formation.</title><p>To determine the role of the CHAMP1 complex in alleviating RS, we conducted a series of assays in CHAMP1 knockout (KO) RPE1<sup>p53&#8722;/&#8722;</sup> cells (<xref rid="fig01" ref-type="fig">Fig. 1</xref>). CHAMP1-deficient cells exhibited increased sensitivity to RS-inducing agents, including HU (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">A</italic></xref>), aphidicolin (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">B</italic></xref>), and cisplatin (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">C</italic></xref>). Similar sensitivity was observed in POGZ-deficient RPE cells, consistent with POGZ&#8217;s role as a CHAMP1 interactor (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pnas.org/lookup/doi/10.1073/pnas.2525144122#supplementary-materials" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S1</ext-link>). Upon HU treatment, CHAMP1 KO cells exhibited increased levels of RS markers, including phosphorylated KAP1 and CHK1, in a time-dependent manner (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">D</italic></xref>), indicating an exacerbated RS response. These cells were also more sensitive to ATR inhibition (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">E</italic></xref>), which impairs the RS response (<xref rid="r4" ref-type="bibr">4</xref>, <xref rid="r36" ref-type="bibr">36</xref>). Furthermore, CHAMP1 depletion significantly increased chromosomal bridges and micronuclei formation (<xref rid="fig01" ref-type="fig">Fig. 1 <italic toggle="yes">F</italic>, <italic toggle="yes">G</italic></xref>), indicative of replication catastrophe and genome instability (<xref rid="r4" ref-type="bibr">4</xref>, <xref rid="r37" ref-type="bibr">37</xref>, <xref rid="r38" ref-type="bibr">38</xref>).</p><fig position="float" fig-type="featured" id="fig01" orientation="portrait"><label>Fig. 1.</label><caption><p>Loss of CHAMP1 results in heightened sensitivity to replication stress (RS) and increased micronuclei formation. (<italic toggle="yes">A</italic>&#8211;<italic toggle="yes">C</italic>) Colony survival plots of RPE1<sup>p53&#8722;/&#8722;</sup> and RPE1<sup>p53&#8722;/&#8722; CHAMP1&#8722;/&#8722;</sup> cells following treatment with varying concentrations of hydroxyurea (HU) (<italic toggle="yes">A</italic>), aphidicolin (<italic toggle="yes">B</italic>), or cisplatin (<italic toggle="yes">C</italic>) for 10 d. Data represent mean &#177; SD from three independent experiments. Statistical significance was determined by two-way ANOVA, **<italic toggle="yes">P</italic> &lt; 0.01; ****<italic toggle="yes">P</italic> &lt; 0.0001. (<italic toggle="yes">D</italic>) Western blot analysis of RS response signaling from RPE1<sup>p53&#8722;/&#8722;</sup> and RPE1<sup>p53&#8722;/&#8722; CHAMP1&#8722;/&#8722;</sup> cells after 2, 4, or 8 h 4 mM HU treatment. The Western blots are representative of two independent experiments. (<italic toggle="yes">E</italic>) Colony survival plots of RPE1<sup>p53&#8722;/&#8722;</sup> and RPE1<sup>p53&#8722;/&#8722; CHAMP1&#8722;/&#8722;</sup> cells treated with different concentrations of ATR inhibitor M1774 for 10 d. Data show mean &#177; SD from three independent experiments. Statistical analysis was performed using two-way ANOVA, ****<italic toggle="yes">P</italic> &lt; 0.0001. (<italic toggle="yes">F</italic>) (<italic toggle="yes">Left</italic>) Representative images of cells with and without a chromosome bridge. The arrow points to a chromosome bridge. Nuclei were stained with DAPI. (Scale bar, 5 &#181;m.) (<italic toggle="yes">Right</italic>) Quantification of the percentage of interphase cells containing chromosome bridges. Data represent mean &#177; SD from three independent experiments, counting &gt;100 cells per experiment. <italic toggle="yes">P</italic> values were calculated using a two-tailed Student&#8217;s <italic toggle="yes">t</italic> test, **<italic toggle="yes">P</italic> &lt; 0.01. (<italic toggle="yes">G</italic>) (<italic toggle="yes">Left</italic>) Representative images of cells with and without micronuclei. The arrow points to micronuclei. Nuclei were stained with DAPI. (Scale bar, 5 &#181;m.) (<italic toggle="yes">Right</italic>) Quantification of the percentage of interphase cells containing micronuclei. Data represent mean &#177; SD from three independent experiments, counting &gt;100 cells per experiment. <italic toggle="yes">P</italic> values were calculated using a two-tailed Student&#8217;s <italic toggle="yes">t</italic> test, **<italic toggle="yes">P</italic> &lt; 0.01. (<italic toggle="yes">H</italic>) Schematic of CHAMP1 mutants from EBV-immortalized lymphoblast cell lines derived from several CHAMP1 patients (Coriell). (<italic toggle="yes">I</italic>) 3-d cytotoxicity analysis of normal and CHAMP1 patient lymphoblasts treated with various concentrations of HU. Cell viability was measured using CellTiter Glo (Promega). Data represent mean &#177; SD from three independent experiments.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pnas.2525144122fig01.jpg"><alt-text>A multi-part figure shows survival plots, western blot analysis, and schematics of CHAMP 1 mutants and cytotoxicity analysis.</alt-text></graphic></fig><p>Importantly, EBV-immortalized lymphoblastoid cell lines (Coriell) derived from CHAMP1 syndrome patients, who carry a heterozygous CHAMP1 mutation express truncated CHAMP1 proteins lacking the C-terminal HP1&#945;-binding domain (<xref rid="r13" ref-type="bibr">13</xref>) (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">H</italic></xref>). These mutant proteins may act in a dominant negative manner or destabilize the protein, resulting in haploinsufficiency and disrupt heterochromatin assembly in these heterozygous cells. Notably, these patient-derived cells are also hypersensitive to HU (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">I</italic></xref>), suggesting a compromised RS response. Collectively, these findings demonstrate that the CHAMP1 complex is essential for maintaining genome integrity under RS conditions.</p></sec><sec id="s3"><title>CHAMP1 Complex Promotes Replication Fork Stability and Facilitates Restart Under Stress.</title><p>To further investigate the role of the CHAMP1 complex in the cellular response to RS, we first examined its localization to replication forks. Using the SIRF (in situ analysis of protein interactions at DNA replication forks) assay (<xref rid="r39" ref-type="bibr">39</xref>, <xref rid="r40" ref-type="bibr">40</xref>) which combines proximity ligation chemistry with EdU (5-Ethynyl-2&#8217;-deoxyuridine) labeling of nascent DNA, we confirmed that CHAMP1 is recruited to stalled replication forks by HU treatment (<xref rid="fig02" ref-type="fig">Fig. 2 <italic toggle="yes">A</italic> and <italic toggle="yes">B</italic></xref>). Complementary experiments using native IdU (5-iodo-2&#8242;-deoxyuridine) staining revealed that HU treatment elevates single-stranded DNA (ssDNA) levels in RPE1<sup>p53&#8722;/&#8722;</sup> cells, which is a marker of RS (<xref rid="r41" ref-type="bibr">41</xref>). Notably, CHAMP1-deficient cells exhibited higher baseline ssDNA, which was further amplified by HU treatment (<xref rid="fig02" ref-type="fig">Fig. 2 <italic toggle="yes">C</italic> and <italic toggle="yes">D</italic></xref>), indicating an inherent vulnerability to RS in the absence of CHAMP1.</p><fig position="float" fig-type="figure" id="fig02" orientation="portrait"><label>Fig. 2.</label><caption><p>Loss of CHAMP1 results in replication fork instability and restart defect. (<italic toggle="yes">A</italic>) Representative images of proximity ligation assay (PLA) showing CHAMP1 localization at replication sites (CHAMP1-EdU PLA, red). Nuclei were stained with DAPI (blue). (Scale bar, 5 &#181;m.) Cells were pulse-labeled with EdU (20 &#956;M) for 20 min, followed by treatment with either 4 mM HU or DMSO for 2 h. (<italic toggle="yes">B</italic>) Distribution of the total intensity of all CHAMP1-EdU PLA spots per nucleus in RPE1<sup>p53&#8722;/&#8722;</sup> cells treated with HU or DMSO. More than 50 cells were counted for each of the three independent experiments. <italic toggle="yes">P</italic> values were calculated using the Mann&#8211;Whitney test, ****<italic toggle="yes">P</italic> &lt; 0.0001. (<italic toggle="yes">C</italic>) <italic toggle="yes">Left</italic>: Representative images of IdU staining without denaturation, indicating regions of single-stranded DNA (ssDNA). Nuclei were stained with DAPI (blue). (Scale bar, 20 &#181;m.) Cells were incubated with IdU for 48 h and subsequently treated with either 4 mM HU or DMSO for 2 h. (<italic toggle="yes">D</italic>) Distribution of the total intensity of IdU per nucleus in RPE1<sup>p53&#8722;/&#8722;</sup> or RPE1<sup>p53&#8722;/&#8722;CHAMP1&#8722;/&#8722;</sup> cells treated with HU or DMSO. More than 50 cells were counted for each of the three independent experiments. <italic toggle="yes">P</italic> values were calculated using the Mann&#8211;Whitney test, ****<italic toggle="yes">P</italic> &lt; 0.0001. (<italic toggle="yes">E</italic>) <italic toggle="yes">Top</italic>: Representative images of DNA fibers illustrating replication fork degradation. Cells were sequentially labeled with CIdU and IdU for 45 min each, followed by treatment with either 4 mM HU or DMSO for 4 h before performing the DNA fiber assay. <italic toggle="yes">Bottom</italic>: Quantification of replication fork degradation, shown as the ratio of IdU to CIdU tract lengths. Each dot represents an individual fiber, with more than 200 fibers analyzed per condition. Statistical significance was determined using the Mann&#8211;Whitney <italic toggle="yes">U</italic> test, ****<italic toggle="yes">P</italic> &lt; 0.0001. (<italic toggle="yes">F</italic>) <italic toggle="yes">Top</italic>: Representative DNA fiber images showing replication fork restart. Cells were labeled with CIdU, treated with 4 mM HU for 1 h, then released into IdU for 45 min before performing the DNA fiber assay. <italic toggle="yes">Bottom</italic>: Quantification of replication fork restart, shown as the IdU tract lengths. Each dot represents an individual fiber, with more than 200 fibers analyzed per condition. Horizontal bars indicate medians. Statistical significance was calculated using the Mann&#8211;Whitney <italic toggle="yes">U</italic> test, ****<italic toggle="yes">P</italic> &lt; 0.0001. (<italic toggle="yes">G</italic>) RPE1<sup>p53&#8722;/&#8722;</sup> or RPE1<sup>p53&#8722;/&#8722;CHAMP1&#8722;/&#8722;</sup> cells were treated with siControl or siMRE11, and then incubated with IdU for 48 h, followed by treatment with either 4 mM HU or DMSO for 2 h. The total intensity of IdU per nucleus was quantified. For each of three independent experiments, more than 50 cells were analyzed. <italic toggle="yes">P</italic> values were calculated using the Mann&#8211;Whitney test, ****<italic toggle="yes">P</italic> &lt; 0.0001. (<italic toggle="yes">H</italic> and <italic toggle="yes">I</italic>) RPE1<sup>p53&#8722;/&#8722;</sup> or RPE1<sup>p53&#8722;/&#8722;CHAMP1&#8722;/&#8722;</sup> cells treated with siMRE11 (<italic toggle="yes">H</italic>) or the MRE11 inhibitor Mirin (<italic toggle="yes">I</italic>), then sequentially labeled with CIdU and IdU for 45 min each. After labeling, cells were exposed to 4 mM HU or DMSO for 4 h before DNA fiber assays were performed. Replication fork degradation was quantified by calculating the IdU/CIdU tract length ratio. At least 200 fibers were analyzed per condition. Statistical significance was determined using the Mann&#8211;Whitney <italic toggle="yes">U</italic> test (****<italic toggle="yes">P</italic> &lt; 0.0001).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pnas.2525144122fig02.jpg"><alt-text>A multi-part figure shows CHAMP 1 localization, replication fork degradation, and I d U intensity in R P E 1 p 53 cells with various treatments.</alt-text></graphic></fig><p>Further analysis using DNA fiber assays provided insights into replication fork dynamics. Upon HU treatment, CHAMP1&#8722;/&#8722; cells revealed a marked decrease in the IdU/CldU tract length ratio (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">E</italic></xref>), indicating increased nascent fork degradation&#8212;an observation that mirrors the established role of BRCA1 in fork protection (<xref rid="r42" ref-type="bibr">42</xref>). Similar fork degradation was observed in POGZ-deficient RPE-1 cells (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pnas.org/lookup/doi/10.1073/pnas.2525144122#supplementary-materials" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S2<italic toggle="yes">A</italic></ext-link>), and POGZ knockdown in CHAMP1 knockout cells did not further exacerbate the phenotype (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pnas.org/lookup/doi/10.1073/pnas.2525144122#supplementary-materials" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S2<italic toggle="yes">A</italic></ext-link>), suggesting that CHAMP1 and POGZ function together as a complex to regulate stalled replication fork stability. Moreover, CHAMP1 loss impaired replication fork restart, as shown by decreased frequency and shorter length of restarted forks in a modified DNA fiber assay (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">F</italic></xref>). These results suggest that CHAMP1 deficiency not only enhances fork degradation but also impairs the efficient restart of stalled replication forks.</p><p>To assess whether MRE11 mediates fork degradation in the absence of CHAMP1, we first assessed its recruitment to stalled replication forks. As expected, MRE11 was enriched at HU-treated stalled replication forks (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pnas.org/lookup/doi/10.1073/pnas.2525144122#supplementary-materials" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S2 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></ext-link>). Notably, CHAMP1-deficient cells showed a marked increase in MRE11 accumulation at stalled replication forks (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pnas.org/lookup/doi/10.1073/pnas.2525144122#supplementary-materials" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S2 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></ext-link>), suggesting increased MRE11 engagement in fork processing in the absence of CHAMP1. Depletion of MRE11 using siRNA rescued the ssDNA accumulation and fork degradation phenotype in CHAMP1 knockout cells (<xref rid="fig02" ref-type="fig">Fig. 2 <italic toggle="yes">G</italic> and <italic toggle="yes">H</italic></xref>). Similarly, treatment with Mirin, a selective MRE11 inhibitor, interfered with the degradation of the nascent strand (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">I</italic></xref>). These findings indicate that MRE11 is the primary nuclease responsible for fork degradation in CHAMP1-deficient cells. Taken together, the CHAMP1 complex appears to play a critical role in protecting replication forks from MRE11-dependent processing under RS.</p></sec><sec id="s4"><title>CHAMP1 Complex Induces H3K9me3 Accumulation At Stalled Replication Forks.</title><p>We previously demonstrated that CHAMP1 and POGZ form a core complex that assembles and maintains heterochromatin via interaction with HP1&#945; and the methyltransferase, SETDB1 (<xref rid="r13" ref-type="bibr">13</xref>). The complex localizes to H3K9me3&#8208;marked regions (<xref rid="r13" ref-type="bibr">13</xref>). De novo H3K9me3 formation at stalled replication forks is known to be crucial for replication fork integrity (<xref rid="r43" ref-type="bibr">43</xref>). To investigate whether the CHAMP1 complex is involved in this process, we first examined whether RS enhances CHAMP1 complex assembly and promotes H3K9me3 accumulation. Interestingly, brief treatment with HU or aphidicolin increased the interaction between CHAMP1 and its associated partners POGZ, HP1&#945;, and H3K9me3 (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">A</italic></xref>), suggesting that RS induces CHAMP1 complex formation. We next employed the SIRF assay to detect H3K9me3 at nascent DNA after HU treatment. Consistent with previous studies (<xref rid="r43" ref-type="bibr">43</xref>), HU treatment increased H3K9me3 and H3K9me2 at the stressed replication sites (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></xref>). Notably, both histone marks were significantly reduced in CHAMP1 and POGZ knockout cells (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></xref>), indicating that the CHAMP1 complex is essential for proper deposition of H3K9 methylation at stalled forks.</p><fig position="float" fig-type="figure" id="fig03" orientation="portrait"><label>Fig. 3.</label><caption><p>The CHAMP1 complex promotes H3K9me3 accumulation at stalled replication forks. (<italic toggle="yes">A</italic>) Western blot analysis of GFP immunoprecipitates from cells expressing either GFP vector control or GFP-CHAMP1, treated with 4 mM HU or 400 nM aphidicolin (APH) for 2 h. Coimmunoprecipitation was performed to examine the interaction of the indicated protein with endogenous POGZ, HP1&#945;, and H3K9me3. Phosphorylated CHK1 and KAP1 were used as markers of RS. Relative amounts of immunoprecipitated proteins were quantified using ImageJ. Immunoblots are representative of two independent experiments. (<italic toggle="yes">B</italic>) <italic toggle="yes">Top</italic>: Representative PLA images showing H3K9me3 localization at replication sites (H3K9me3-EdU PLA, red). Nuclei were stained with DAPI (blue) (Scale bar, 5 &#181;m.) Cells were pulse-labeled with EdU for 20 min, followed by treatment with either 4 mM HU or DMSO for 2 h. <italic toggle="yes">Bottom</italic>: Quantification of total H3K9me3&#8211;EdU PLA signal intensity per nucleus. More than 50 cells were counted for each of three independent experiments. <italic toggle="yes">P</italic> values were determined using the Mann&#8211;Whitney test (****<italic toggle="yes">P</italic> &lt; 0.0001). (<italic toggle="yes">C</italic>) <italic toggle="yes">Top</italic>: Representative images of PLA depicting H3K9me2 presence at replication sites (H3K9me2-EdU PLA, red). Nuclei were stained with DAPI (blue). (Scale bar, 5 &#181;m.) Cells were treated with EdU for 20 min and were either treated with 4 mM HU or DMSO for 2 h. <italic toggle="yes">Bottom</italic>: Distribution of the total intensity of all H3K9me2-EdU PLA spots per nucleus. More than 50 cells were counted for each of three independent experiments. <italic toggle="yes">P</italic> values were calculated using the Mann&#8211;Whitney test, ****<italic toggle="yes">P</italic> &lt; 0.0001. (<italic toggle="yes">D</italic>) RPE1 cells were transfected with siRNA targeting SETDB1 or a nontargeting control (siCtrl) for 48 h, followed by a 20-min EdU pulse. Cells were then treated with either 4 mM HU or DMSO for 2 h. The total intensity of H3K9me3&#8211;EdU PLA signals per nucleus was quantified. More than 50 cells were counted for each of three independent experiments. <italic toggle="yes">P</italic> values were calculated using the Mann&#8211;Whitney test, ****<italic toggle="yes">P</italic> &lt; 0.0001. (<italic toggle="yes">E</italic>) RPE1<sup>p53&#8722;/&#8722;</sup> or RPE1<sup>p53&#8722;/&#8722;CHAMP1&#8722;/&#8722;</sup> cells were treated with the SETDB1 inhibitor (SETDB1-TTD-IN-1) for 24 h, followed by a 20-min EdU pulse. Cells were then treated with either 4 mM HU or DMSO for 2 h. The total intensity of H3K9me3&#8211;EdU PLA signals per nucleus was quantified. More than 50 cells were counted for each of three independent experiments. <italic toggle="yes">P</italic> values were calculated using the Mann&#8211;Whitney test, ****<italic toggle="yes">P</italic> &lt; 0.0001. (<italic toggle="yes">F</italic>) Quantification of interphase cells containing micronuclei in RPE<sup>p53&#8722;/&#8722;</sup> and RPE<sup>p53&#8722;/&#8722; CHAMP1&#8722;/&#8722;</sup> cells. Cells were treated with either the SETDB1 inhibitor (SETDB1-TTD-IN-1) or DMSO for 24 h before imaging. Data are presented as mean &#177; SD from three independent experiments, with more than 100 cells analyzed per experiment. <italic toggle="yes">P</italic> values were determined using a two-tailed Student&#8217;s <italic toggle="yes">t</italic> test, *<italic toggle="yes">P</italic> &lt; 0.05. (<italic toggle="yes">G</italic>) 3-d cytotoxicity analysis of RPE<sup>p53&#8722;/&#8722;</sup> and RPE<sup>p53&#8722;/&#8722; CHAMP1&#8722;/&#8722;</sup> cells treated with increasing concentrations of HU, with or without the SETDB1 inhibitor (SETDB1-TTD-IN-1). Cell viability was measured using CellTiter-Glo (Promega). Data represent mean &#177; SD from three independent experiments.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pnas.2525144122fig03.jpg"><alt-text>A multi-part figure shows western blot analysis, P L A images, and cytotoxicity analysis of cells.</alt-text></graphic></fig><p>To further investigate the mechanism, we tested whether SETDB1 is responsible for de novo H3K9me3 deposition at stalled replication forks. Interestingly, depletion of the SETDB1 using siRNA or chemical inhibition of SETDB1 abolished the HU-induced H3K9me3&#8211;EdU PLA signals (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">D</italic> and <italic toggle="yes">E</italic></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pnas.org/lookup/doi/10.1073/pnas.2525144122#supplementary-materials" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3 <italic toggle="yes">A</italic> and <italic toggle="yes">B</italic></ext-link>). Notably, SETDB1 inhibition did not further reduce H3K9me3 levels in CHAMP1 knockout cells, suggesting that SETDB1 may function downstream of CHAMP1. Inhibition of SETDB1 also increased micronuclei formation and sensitized cells to HU; however, these phenotypes were not further enhanced in CHAMP1-deficient cells (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">F</italic> and <italic toggle="yes">G</italic></xref>), suggesting that the CHAMP1 and SETDB1 function epistatically in the response to stalled replication forks. Taken together, our results suggest that the CHAMP1&#8211;POGZ complex functions as a key regulator of H3K9me3 deposition at stalled replication forks by coordinating the recruitment and activity of SETDB1 methyltransferase and maintaining replication fork integrity under RS.</p></sec><sec id="s5"><title>CHAMP1 Complex Resolves Telomeric RS in ALT Cells.</title><p>While the CHAMP1 complex appears to play a general role in relieving RS, it may have a more specific role in some cellular settings. For instance, previous studies have shown that tumor cells that use the ALT mechanism for telomere maintenance have very high levels of RS and homology-directed DNA repair at their telomeres (<xref rid="r14" ref-type="bibr">14</xref>, <xref rid="r44" ref-type="bibr">44</xref>, <xref rid="r45" ref-type="bibr">45</xref>) and a high local accumulation of H3K9me3 deposition (<xref rid="r46" ref-type="bibr">46</xref><xref rid="r47" ref-type="bibr"/><xref rid="r48" ref-type="bibr"/>&#8211;<xref rid="r49" ref-type="bibr">49</xref>). Indeed, ALT-positive tumor cells rely on several mechanisms to limit their RS, such as the upregulation of FANCM and SMARCAL1 activity. (<xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r50" ref-type="bibr">50</xref>). We reasoned that the CHAMP1 complex may also play a role in reducing RS in ALT-positive tumors.</p><p>To determine whether the CHAMP1 complex is required for ALT telomere replication, we employed PICh (Proteomics of Isolated Chromatin segments) to profile proteins associated with ALT telomeres in CHAMP1 knockout ALT-positive U2OS cells (<xref rid="r14" ref-type="bibr">14</xref>) (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">A</italic></xref>). CHAMP1 depletion led to elevated levels of FANCM, other Fanconi anemia (FA) proteins, and RS proteins, including ATR, ATRIP, and TOPBP1 (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">B</italic></xref>) at telomeres. Consistently, loss of CHAMP1 or POGZ resulted in increased pRPA2 foci enrichment and damage signal at telomeres (<xref rid="fig04" ref-type="fig">Fig. 4 <italic toggle="yes">C</italic>&#8211;<italic toggle="yes">F</italic></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pnas.org/lookup/doi/10.1073/pnas.2525144122#supplementary-materials" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S4 <italic toggle="yes">A</italic> and <italic toggle="yes">B</italic></ext-link>). To further study the function of the CHAMP1 complex for telomere replication, we next performed Telo&#8208;FISH (telomere fluorescence in situ hybridization) assays to quantify telomere signals. Remarkably, knockout of CHAMP1 or POGZ significantly increased telomere loss and telomere fragility in U2OS cells (<xref rid="fig04" ref-type="fig">Fig. 4 <italic toggle="yes">G</italic>&#8211;<italic toggle="yes">I</italic></xref>), known readouts of telomere replication defects (<xref rid="r51" ref-type="bibr">51</xref>). Collectively, these findings underscore the significance of the CHAMP1 complex in telomere replication and integrity maintenance of ALT cells.</p><fig position="float" fig-type="figure" id="fig04" orientation="portrait"><label>Fig. 4.</label><caption><p>The CHAMP1 complex reduces telomere RS in ALT cells. (<italic toggle="yes">A</italic>) Schematic of the PICh (Proteomics of Isolated Chromatin segments) strategy used to profile the telomere-associated proteome in WT and sgCHAMP1 U2OS cells. Chromatin was fractionated and hybridized with a biotinylated telomeric probe and captured using magnetic beads. Telomere-bound proteins were subsequently identified by mass spectrometry. (<italic toggle="yes">B</italic>) Scatterplot showing the Log2(sgCHAMP1/ WT) values of total peptide counts from telomere-enriched proteomes in WT and sgCHAMP1 U2OS cells. RS response proteins are highlighted. (<italic toggle="yes">C</italic>) Representative confocal images showing colocalization of phosphorylated RPA2 (pRPA2-S33) with TRF2 in WT, sgCHAMP1 (sgC), and sgPOGZ (sgP) U2OS cells. The arrow indicates pRPA2-TRF2 colocalization. Nuclei were counterstained with DAPI. (Scale bar, 5 &#956;m.) (<italic toggle="yes">D</italic>) Quantification of pRPA2-TRF2 colocalizations in (<italic toggle="yes">C</italic>). Data represent mean &#177; SEM from three independent experiments, with more than 50 cells analyzed per experiment. <italic toggle="yes">P</italic> values were determined using the Mann&#8211;Whitney <italic toggle="yes">U</italic> test (****<italic toggle="yes">P</italic> &lt; 0.0001). (<italic toggle="yes">E</italic>) Representative confocal images showing colocalization of &#947;H2AX with TRF2 in WT, sgCHAMP1 (sgC), and sgPOGZ (sgP) U2OS cells. The arrow indicates &#947;H2AX-TRF2 colocalization. Nuclei were counterstained with DAPI. (Scale bar, 5 &#956;m.) (<italic toggle="yes">F</italic>) Quantification of &#947;H2AX-TRF2 colocalizations in (<italic toggle="yes">E</italic>). Data represent mean &#177; SEM from three independent experiments, with more than 50 cells analyzed per experiment. <italic toggle="yes">P</italic> values were determined using the Mann&#8211;Whitney <italic toggle="yes">U</italic> test (****<italic toggle="yes">P</italic> &lt; 0.0001). (<italic toggle="yes">G</italic>) Representative images of chromosomes showing normal telomeres, telomere loss (arrow), and fragile telomeres (arrowhead). (<italic toggle="yes">H</italic> and <italic toggle="yes">I</italic>) Quantification of telomere loss (<italic toggle="yes">H</italic>) and telomere fragility (<italic toggle="yes">I</italic>) per metaphase spread in WT, CHAMP1-knockout (sgC), and POGZ-knockout (sgP) U2OS cells. More than 50 metaphase spreads were analyzed per experiment. <italic toggle="yes">P</italic> values were determined using the Mann&#8211;Whitney <italic toggle="yes">U</italic> test (****<italic toggle="yes">P</italic> &lt; 0.0001). (<italic toggle="yes">J</italic>) Colony survival assay showing the survival of WT and CHAMP1-knockout (sgC) U2OS cells treated with sgFANCM (sgF). <italic toggle="yes">P</italic> values were determined using a two-tailed Student&#8217;s <italic toggle="yes">t</italic> test (*<italic toggle="yes">P</italic> &lt; 0.05; **<italic toggle="yes">P</italic> &lt; 0.01; ***<italic toggle="yes">P</italic> &lt; 0.001). (<italic toggle="yes">K</italic>) A 10-d clonogenic survival of WT, sgCHAMP1, and sgPOGZ U2OS cells treated with increasing concentrations of FANCMi (FANCM-BTR PPI-IN-1, a disruptor of the FANCM/ BTR interaction which hampers the FANCM localization to telomeres).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pnas.2525144122fig04.jpg"><alt-text>A multi-part figure shows telomere replication. It includes a schematic, scatterplot, confocal images, graphs of telomere loss, and survival assays.</alt-text></graphic></fig><p>The ATR and FANCM proteins are highly enriched in ALT-positive telomeres and may function to alleviate RS and to maintain tumor cell viability (<xref rid="r8" ref-type="bibr">8</xref>, <xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r52" ref-type="bibr">52</xref>, <xref rid="r53" ref-type="bibr">53</xref>). Given the critical role of FANCM in maintaining genome stability in ALT-positive cells, FANCM inhibitors have emerged as promising therapeutic agents for the effective suppression of ALT-driven tumors. Remarkably, simultaneous knockout of CHAMP1 and FANCM induces synthetic lethality in U2OS cells (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">J</italic></xref>). Moreover, ALT cells deficient in CHAMP1 complex subunits exhibit significantly increased sensitivity to a FANCM inhibitor (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">K</italic></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pnas.org/lookup/doi/10.1073/pnas.2525144122#supplementary-materials" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S4<italic toggle="yes">C</italic></ext-link>), highlighting a potential synthetic lethal strategy for targeting ALT-associated cancers. Taken together, knockout of the CHAMP1 complex increases telomere RS and sensitizes the ALT cells to drugs which further increase RS.</p></sec><sec id="s6"><title>Cancer Cells Under RS Are Dependent On the CHAMP1 Complex.</title><p>High-grade ovarian cancer and many cancers undergo RS due to amplification of oncogene cyclin E1 (CCNE1) (<xref rid="r41" ref-type="bibr">41</xref>). To study how tumors survive under elevated RS, we performed gene expression and dependency analyses on breast and ovarian cancer cells with CCNE1 amplification. Consistent with previous findings, DepMap data analysis revealed that FA complex mRNA levels strongly correlate with CCNE1 mRNA expression (<xref rid="fig05" ref-type="fig">Fig. 5<italic toggle="yes">A</italic></xref>). Interestingly, DepMap data analysis also revealed that CHAMP1 complex mRNA levels strongly correlate with CCNE1 mRNA expression (<xref rid="fig05" ref-type="fig">Fig. 5<italic toggle="yes">A</italic></xref>). Consistently, protein analysis confirmed high CHAMP1 levels in CCNE1-amplified ovarian cancer cells (<xref rid="fig05" ref-type="fig">Fig. 5 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></xref>). Importantly, CHAMP1 depletion selectively impaired viability in CCNE1-amplified cancer cell lines (<xref rid="fig05" ref-type="fig">Fig. 5<italic toggle="yes">D</italic></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pnas.org/lookup/doi/10.1073/pnas.2525144122#supplementary-materials" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S5</ext-link>). Moreover, TCGA analysis showed that high CHAMP1 expression predicted worse survival in patients with CCNE1-amplified tumors, but not in those without amplification (<xref rid="fig05" ref-type="fig">Fig. 5 <italic toggle="yes">E</italic> and <italic toggle="yes">F</italic></xref>). These results highlight a potential oncogene-induced dependency on the CHAMP1 complex, revealing therapeutic opportunities in cancers driven by RS.</p><fig position="float" fig-type="figure" id="fig05" orientation="portrait"><label>Fig. 5.</label><caption><p>Cancer cells with RS are highly dependent on CHAMP1. (<italic toggle="yes">A</italic>) Volcano plot showing the genes coexpressed with CCNE1. RS response proteins and the CHAMP1 complex were highlighted. (<italic toggle="yes">B</italic>) CHAMP1 protein levels positively correlate with CCNE1 (Cyclin E1) mRNA expression in ovarian and uterine cancer cell lines. (<italic toggle="yes">C</italic>) Immunoblot analysis of ovarian cancer cell lines with or without <italic toggle="yes">CCNE1</italic> amplification (amp) using the indicated antibodies. GAPDH acts as a loading control. (<italic toggle="yes">D</italic>) Survival assay of ovarian cancer cell lines treated with siControl or siCHAMP1 for three days. <italic toggle="yes">P</italic> values were calculated by a two-tailed Student&#8217;s <italic toggle="yes">t</italic> test (**<italic toggle="yes">P</italic> &lt; 0.01; ***<italic toggle="yes">P</italic> &lt; 0.001). (<italic toggle="yes">E</italic> and <italic toggle="yes">F</italic>) Kaplan&#8211;Meier survival curves showing overall survival of patients from TCGA with high CHAMP1 expression, stratified by <italic toggle="yes">CCNE1</italic> amplification status: <italic toggle="yes">CCNE1</italic>-amplified (CCNE1-AMP) (<italic toggle="yes">E</italic>) and nonamplified (CCNE1-NONAMP) (<italic toggle="yes">F</italic>). This analysis combines tumors of all cancer types from TCGA studies. N represents the number of patients.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pnas.2525144122fig05.jpg"><alt-text>A six panel figure shows: A) Volcano plot, B) Scatter plot, C) Immunoblot analysis, D) Vertical bar graph, E and F) Kaplan Meier survival curves.</alt-text></graphic></fig></sec></sec><sec sec-type="discussion" id="s7"><title>Discussion</title><p content-type="flushleft">Our recent study indicates that the CHAMP1 complex is involved in heterochromatin assembly at multiple genomic locations (<xref rid="r13" ref-type="bibr">13</xref>). The CHAMP1 complex interacts with and recruits the methyltransferase SETDB1, leading to H3K9me3 deposition, which in turn facilitates telomere clustering and promotes homologous recombination (HR) at these sites (<xref rid="r13" ref-type="bibr">13</xref>). We now demonstrate that the CHAMP1 complex plays a more general role in the reduction of cellular RS. Accordingly, loss of CHAMP1 or its direct interactor POGZ results in basal and HU-inducible ssDNA accumulation, a hallmark of RS. Deleting CHAMP1 led to an increase in the activation of the DNA damage checkpoint ATR/CHK1 pathway (<xref rid="r41" ref-type="bibr">41</xref>). CHAMP1-deficient cells are hypersensitive to inhibitors of the ATR/CHK1 pathway and the Fanconi Anemia (FA) pathway.</p><p>Mechanistically, we demonstrate that the CHAMP1 complex safeguards stalled replication forks through several coordinated mechanisms (<xref rid="fig06" ref-type="fig">Fig. 6</xref>). First, it promotes the deposition of H3K9me3 via recruitment and activation of SETDB1, establishing a repressive chromatin environment that stabilizes the fork. Second, it limits excessive DNA end resection by blocking recruitment of the MRE11 nuclease, thereby protecting nascent DNA from degradation. Together, these activities preserve fork integrity and maintain genome stability under conditions of RS.</p><fig position="float" fig-type="figure" id="fig06" orientation="portrait"><label>Fig. 6.</label><caption><p>Schematic model illustrating how the CHAMP1 complex regulates stalled replication fork stability. The CHAMP1 complex&#8212;comprising CHAMP1, POGZ, HP1&#945;, and SETDB1&#8212;plays a critical role in maintaining the stability of stalled replication forks under RS, which can arise from repetitive DNA sequences, oncogene amplification, or exogenous agents. This complex functions through multiple coordinated mechanisms: 1) it promotes the deposition of H3K9me3 via recruitment and activation of the SETDB1 methyltransferase, establishing a heterochromatic environment at stalled forks; 2) it prevents excessive resection by inhibiting the recruitment of the MRE11 nuclease, thereby protecting nascent DNA from degradation. Together, these actions ensure replication fork integrity and safeguard genome stability during conditions of RS.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pnas.2525144122fig06.jpg"><alt-text>Diagram of CHAMP 1 complex regulating stalled replication fork stability, including M R E 11, P O G Z, H P 1 alpha, S E T D B 1, and H 3 K 9 me 3.</alt-text></graphic></fig><p>Previous studies have shown that H3K9me3 enrichment at stalled replication forks is also mediated by G9a and is critical for maintaining fork integrity (<xref rid="r43" ref-type="bibr">43</xref>). These studies suggest that multiple H3K9 methyltransferases may modulate heterochromatin formation at stressed forks. Future studies are needed to elucidate how SETDB1 and G9a dynamically regulate H3K9 methylation at stalled replication forks, and how their coordinated activity potentially orchestrated by CHAMP1 contributes to fork stabilization and genome integrity.</p><p>Telomeres maintained by the ALT pathway exhibit elevated RS (<xref rid="r45" ref-type="bibr">45</xref>). Loss of CHAMP1 further elevates RS at these sites, as evidenced by increased recruitment of proteins from the ATR/CHK1 and FA pathways, including FANCM (<xref rid="r54" ref-type="bibr">54</xref>). These cells also show hypersensitivity to inhibitors of ATR or FANCM, highlighting a functional dependency on these RS response mechanisms, especially when the function of the CHAMP1 complex is compromised.</p><p>Beyond cellular models, our findings have important clinical implications. Individuals carrying de novo heterozygous mutations in CHAMP1 develop CHAMP1 syndrome, a neurodevelopmental disorder characterized by global developmental delay, severe speech impairment, intellectual disability, behavioral abnormalities such as autism spectrum and ADHD-like features, and distinctive craniofacial dysmorphisms (<xref rid="r22" ref-type="bibr">22</xref><xref rid="r23" ref-type="bibr"/><xref rid="r24" ref-type="bibr"/><xref rid="r25" ref-type="bibr"/>&#8211;<xref rid="r26" ref-type="bibr">26</xref>). A recent study indicates that rare patients with CHAMP1 syndrome develop leukemia, suggesting a broader role of the CHAMP1 complex in limiting RS and maintaining the genomic stability of hematopoietic stem and progenitor cells (<xref rid="r22" ref-type="bibr">22</xref>). A closely related neurodevelopmental disorder, White&#8211;Sutton syndrome (WSS), arises from de novo heterozygous mutations in the POGZ gene (<xref rid="r27" ref-type="bibr">27</xref><xref rid="r28" ref-type="bibr"/><xref rid="r29" ref-type="bibr"/><xref rid="r30" ref-type="bibr"/><xref rid="r31" ref-type="bibr"/><xref rid="r32" ref-type="bibr"/><xref rid="r33" ref-type="bibr"/><xref rid="r34" ref-type="bibr"/>&#8211;<xref rid="r35" ref-type="bibr">35</xref>). Using EBV-transformed peripheral blood lymphoblasts from patients with CHAMP1 syndrome, we have demonstrated a cellular defect in heterochromatinization and homologous recombination, based on the reduction in RAD51 foci assembly. These patient-derived lymphoblastoid cell lines (LCLs) also display marked HU hypersensitivity, reinforcing the conclusion that CHAMP1 deficiency leads to elevated baseline RS. Whether LCLs from WSS patients have similar RS and HU sensitivity remains to be determined.</p><p>RS in tumor cells can result from several mechanisms, including loss of the p53 protein, mitogenic enhancement from oncoprotein expression, or disruption of DNA repair pathways. Cancer cells with RS upregulate the ATR/CHK1 pathway as a mechanism to enhance cell cycle checkpoints and to slow down cell growth. We reasoned that upregulation of the CHAMP1 complex might provide an independent mechanism for allowing cancer cells to tolerate their RS. Consistent with this hypothesis, we have shown that cancer cells that are driven by CCNE1 amplification not only exhibit upregulated expression of CHAMP1 and POGZ but are also functionally dependent on these factors for survival under RS conditions.</p><p>In summary, the CHAMP1 complex has a broad role in the cellular response to stalled forks by promoting H3K9me3 enrichment via SETDB1 and preventing nascent DNA degradation through inhibition of MRE11 recruitment. Disruption of the CHAMP1 complex, or inhibition of its associated methyltransferase SETDB1, may offer a therapeutic strategy to exacerbate RS and genomic instability in cancer cells, thereby selectively eliminating tumor cells. Moreover, as CHAMP1 and POGZ mutations are also associated with neurodevelopmental disorders, further studies into their functions may provide broader insights into both tumorigenesis and human genetic disease.</p><p>Future studies will address the actual functional role of transient heterochromatin assemblyat the stalled replication fork. This assembly could alter the three-dimensional structure of the fork or could result in the recruitment of additional proteins required for homologous recombination, fork stability, and restart. Also, it will be important to determine whether the CHAMP1 complex promotes heterochromatin assembly at specific regions of the genome beyond telomeres. While we have shown that loss of the CHAMP1 complex causes RS, it remains unclear whether this loss can lead to aberrant transcription or significant chromosomal instability. Finally, how the CHAMP1 heterozygous mutations result in the conserved neurodevelopmental defects of CHAMP1 syndrome remains unknown.</p></sec><sec sec-type="materials|methods" id="s8"><title>Materials and Methods</title><sec id="s9"><title>Cell Culture.</title><p>Human U2OS and RPE1-hTERT cells were maintained in DMEM/F12 supplemented with Glutamax (Invitrogen), 10% FBS (Sigma) and 1% penicillin-streptomycin (Invitrogen). HEK293T cells were cultured in DMEM (Thermo Fisher) supplemented with 10% FBS and 1% penicillin-streptomycin. Cell lines were obtained from the American Type Culture Collection (ATCC) and validated by short tandem repeat (STR) testing. CHAMP1 patient derived lymphocyte cell lines were obtained from Coriell Institute and were cultured in RPMI1640 supplemented with 15% FBS (sigma) and 1% penicillin-streptomycin (Thermo Fisher). Cell lines were maintained at 37 &#176;C with 5% CO<sub>2</sub> under normal culture conditions. All cell lines were tested for <italic toggle="yes">Mycoplasma</italic> contamination using the MycoAlert Plus <italic toggle="yes">Mycoplasma</italic> Detection Kit (Lonza).</p></sec><sec id="s10"><title>RNA Interference and CRISPR-Mediated Gene Deletions.</title><p>siRNA knockdown and CRISPR knockout were performed as previously described (<xref rid="r13" ref-type="bibr">13</xref>). For siRNA knockdown, cells were transfected using RNAiMax (Invitrogen, #13778150) according to the manufacturer&#8217;s protocols. List of siRNA used are listed in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pnas.org/lookup/doi/10.1073/pnas.2525144122#supplementary-materials" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S3</ext-link> for. Knockdown efficiency was confirmed by Western blot or qPCR analysis (HiScript IV All-in-One Ultra RT SuperMix for qPCR, Vazyme). For single-gene knockout, sgRNAs targeting candidate genes were cloned into the pSpCas9 BB-2A-GFP (PX458) vector (GenScript) or codelivered with Cas9 protein via electroporation (Lonza), following the manufacturer&#8217;s protocol. sgRNA sequences used are listed in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pnas.org/lookup/doi/10.1073/pnas.2525144122#supplementary-materials" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S3</ext-link>. For PX458-mediated transfections, GFP-positive cells were isolated 48 h posttransfection using a BD FACSAria II cell sorter. The resulting knockdown and knockout efficiency were validated by western blotting.</p></sec><sec id="s11"><title>SIRF/Proximity Ligation Assay.</title><p>The SIRF assay was performed as previously described (<xref rid="r55" ref-type="bibr">55</xref>). Cells were seeded on 10 mm coverslips in 24-well plated until reaching 60% confluence and then treated with SETDB1 inhibitors for 16 h. Cells were incubated with EdU (5-ethynyl-2&#8217;-deoxyuridine) (Invitrogen, A10044) (20 &#181;M) for 20 min to label nascent DNA. Cells were treated with hydroxyurea (4 mM) for 2 h to induce replication fork stalling. Coverslips were washed with 1X PBS and subsequently permeabilized with 0.5 Triton X-100 for 5 min. Cells were then fixed with 4% paraformaldehyde for 10 min at room temperature. Cells were washed twice with 1X PBS and then incubated in blocking buffer (3% BSA in 0.1 Triton X-100) for 1 h at room temperature. Following blocking, cells were incubated in click reaction mix [1X PBS, Copper (II) sulfate pentahydrate (5 mM) (Sigma Aldrich, #203165-10G), Biotin Azide (PEG4 carboxamide-6-Azidohexanyl Biotin) (10 &#956;M) (Life Technologies, #<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="B10184">B10184</ext-link>), and sodium ascorbate (10 mM) (Santa Cruz Biotechnology, #SC-215877)] for 30 min protected from light. Coverslips were incubated with primary antibodies overnight at 4 &#176;C: mouse &#945;-biotin (Thermo Fisher Scientific, #NC9724635) (1:1,000 dilution), rabbit &#945;-H3K9me3 (Abcam, #ab8898-100ug) (1:1,000 dilution), rabbit &#945;-H3K9me2 (Abcam, #ab1220).</p><p>After primary antibody incubation, coverslips were treated with Duolink In Situ PLA Probe Anti-Rabbit PLUS (DUO92002) and Duolink In Situ PLA Probe Anti-Mouse MINUS (DUO92004), according to the manufacturer&#8217;s instructions. The Duolink In situ detection kit (DUO92008) was used for the ligation and amplification of the PLA signal. Coverslips were mounted with Prolong diamond antifade reagent with DAPI (ThermoFisher Scientific, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="P36971">P36971</ext-link>). Images were acquired using a Zeiss microscope and analyzed with Cell Profiler.</p></sec><sec id="s12"><title>Immunofluorescence Assay.</title><p>Cells were seeded onto glass coverslips in 24-well plates. For immunofluorescence, cells were pre-extracted with 0.5% Triton X-100 for 5 min, followed by fixation in 4% paraformaldehyde for 10 min at 4 &#176;C. After three washes with PBS, cells were blocked with 3% BSA in PBS for 1 h at room temperature. Coverslips were incubated with primary antibodies overnight at 4 &#176;C, followed by secondary antibody incubation for 1 h at room temperature. Coverslips were mounted with DAPI (Vector Laboratories) and imaged on a Zeiss AX10 fluorescence microscope using Zen software.</p></sec><sec id="s13"><title>Immunoprecipitation.</title><p>Immunoprecipitation was carried out as previously described (<xref rid="r14" ref-type="bibr">14</xref>) with minor modifications. Following 48 h of GFP-CHAMP1 plasmid transfection, 293 T cells were treated with HU, APH, or DMSO for 2 h. Cells were collected and washed with PBS, and resuspended in hypotonic buffer [10 mM HEPES pH 7.4, 10 mM KCl, 0.05% NP-40, and proteinase and phosphatase inhibitor cocktail (Thermo, 1:100)] on ice for 20 min and followed by centrifugation at 14,000 rpm at 4 &#176;C. Nuclei were collected, washed again with hypotonic buffer, and centrifuged at 14,000 rpm at 4 &#176;C. Nuclei were then lysed in IP buffer [100 mM NaCl, 0.2% NP-40, 1 mM MgCl2, 10% glycerol, 5 mM NaF, 50 mM Tris-HCl pH 7.5, 50 U mL<sup>&#8211;1</sup> benzonase (Sigma-Aldrich), and proteinase and phosphatase inhibitor cocktail (Thermo, 1:100)] for 1 h on ice and subsequently spun down at 14,000 rpm at 4 &#176;C. The supernatant was collected, and the NaCl and EDTA concentrations were adjusted to 150 mM and 2 mM, respectively. Protein concentrations were quantified and normalized, with 10% of lysate used as input. The remaining lysates were incubated with GFP-Trap_A (Chromotek) overnight at 4 &#176;C. Beads were washed four times with IP buffer, and the immunoprecipitated proteins were eluted by boiling. Western blot analysis was performed to detect the immunoprecipitants.</p></sec><sec id="s14"><title>Western Blot Analysis.</title><p>Cells were lysed on ice for 10 min using 1X RIPA buffer (Cell Signaling Technology, #9806) with protease and phosphatase inhibitors. After centrifugation at 15,000 rpm for 10 min at 4 &#176;C, the supernatant was collected, combined with equal volume of 2&#215; Laemmli sample buffer (BioRad #1610737) and boiled at 100 &#176;C for 10 min. Lysates were separated on precast gels and transferred to nitrocellulose membranes. Membranes were blocked in 5% milk/TBST, incubated with primary and secondary antibodies, signals were detected by immunofluorescence using an ODYSSEY CLx machine with ImageStudio Ver. 5.2.</p></sec><sec id="s15"><title>Telomere-FISH.</title><p>Quantitative telomere FISH (Fluorescence In Situ Hybridization) was carried out following previously established methods (<xref rid="r56" ref-type="bibr">56</xref>). Briefly, cells were synchronized by treatment with nocodazole (0.5 mg/mL) for 4 TO 6 h, harvested and incubated in 0.075 M KCl at 37 &#176;C for 25 min. After hypotonic treatment, cells were fixed in methanol/acetic acid (3:1) at &#8722;20 &#176;C overnight and then spread to slides. Telomere labeling was performed using a TelG-Cy3 PNA probe (PNAbio) according to standard protocols.</p></sec><sec id="s16"><title>Clonogenic Assays.</title><p>After counting, cells were seeded in triplicate into 6-cell plates for colony formation assays. After 24 h, they were treated with different concentrations of drugs and incubated for 10 d. Cells were fixed in 4% formaldehyde for 10 min at room temperature and subsequently stained with crystal violet for 30 min. Cell growth area quantification and imaging of the plates were performed using GelCount (Oxford Optronix).</p></sec><sec id="s17"><title>CellTiter-Glo Luminescent Cell Viability Assay.</title><p>CellTiter-Glo survival assays were carried out as previously described (<xref rid="r57" ref-type="bibr">57</xref>). For drug sensitivity testing, cells were plated in 96-well plates at 500 cells per well. 12 h after plating, cells were treated with specified drug concentrations. Cell viability was assessed three days later using the CellTiter-Glo assay (Promega), and survival at each concentration was calculated as a percentage relative to the corresponding untreated control.</p></sec><sec id="s18"><title>Proteomics of Isolated Chromatin segments (PICh).</title><p>PICh assay was carried out as previously described (<xref rid="r13" ref-type="bibr">13</xref>).</p></sec><sec id="s19"><title>Fork Stability and Restart Assay.</title><p>DNA fiber assays (<xref rid="r55" ref-type="bibr">55</xref>) were used to assess replication fork stability and restart. For the fork stability assay, cells were pulse-labeled with 100 &#181;M CldU (5-Chloro-2&#8242;-deoxyuridine, Sigma C6891) for 45 min, followed by 100 &#181;M IdU (5-Iodo-2&#8242;-deoxyuridine, Sigma I7125) for an additional 45 min. Replication forks were stalled by treating the cells with 4 mM JU for 4 h prior to harvesting. For fork restart assay, cells were initially labeled with 100 &#181;M CldU for 45 min, followed by 1 h of 4 mMHU treatment to induce replication fork stalling. Following HU washout, replication fork restart was assessed by labeling with 100 &#181;M IdU for 45 min. DNA fiber assay was performed following the FiberPrep DNA extraction protocol (Genomic Vision, cat# EXT001A). Briefly, cells were resuspended in PBS and embedded in agarose plugs, which were then treated with proteinase K overnight. Agarose plugs were subsequently digested with beta-agarase overnight. The samples were then loaded into FiberComb wells and combed onto silanized coverslips (Genomic Vision, cat# COV-002) using the Molecular Combing System (Genomic Vision). After denaturation, coverslips were incubated overnight at 37 &#186;C with rat anti-BrdU antibody (clone BU1/75 (ICR1), Life Technologies <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="MA182088">MA182088</ext-link>) and mouse anti-IdU Antibody (BD Biosciences 347580) overnight. The following day coverslips were washed with PBS-T (0.05% Tween) and incubated for 45 min at 37 &#176;C with secondary goat anti-rat Cy5 antibody (Abcam cat# ab6565) and goat anti-mouse Cy3 antibody (Abcam cat #97035), followed by mouse anti-ssDNA antibody (cat# DSHB auto anti-ssDNA) for 1 h and 15 min at 37 &#176;C, and goat anti-mouse BV480 (Jackson cat #115-685-166) for 45 min at 37 &#176;C. Coverslips were mounted, and fibers were imaged using FiberVision S. Lengths of IdU tracts or IdU/CldU ratio were quantified by ImageJ and plotted using Prism9 (GraphPad).</p></sec><sec id="s20"><title>Cancer Cell Line Data Acquisition and Analysis.</title><p>Coexpressed genes of CCNE1 were determined by assessing the associations between its mRNA expression and that of all other genes. The Cancer Cell Line Encyclopedia (CCLE) (<xref rid="r58" ref-type="bibr">58</xref>) transcriptomic data used for analysis were generated by the project and were obtained from the DepMap portal (release 19Q4 Public; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://depmap.org/" ext-link-type="uri">https://depmap.org/</ext-link>) at the Broad Institute. The associations between mRNA expression of CCNE and that of every other gene were assessed using the robust linear regressions on the log<sub>2</sub>(TPM+1) mRNA expression values, as computed by the limma (<xref rid="r59" ref-type="bibr">59</xref>) package in R, with robust empirical Bayes moderation and lineage correction. The ggplot2 R package was used to create the volcano plot of the linear regression results.</p><p>The association between CHAMP1 protein expression and CCNE1 mRNA expression was assessed using the multiple linear regression with lineage correction, as computed by GraphPad Prism (version 10.4.2). Human cancer cell lines&#8217; relative protein expression data for CHAMP1 and mRNA expression data [log<sub>2</sub>(TPM+1)] for CCNE1 were downloaded from DepMap (release 24Q4 Public).</p></sec><sec id="s21"><title>TCGA Human Tumor Data Acquisition and Analysis.</title><p>The survival analyses with CHAMP1 expression were conducted using human tumor data generated by The Cancer Genome Atlas Project (TCGA) (<xref rid="r60" ref-type="bibr">60</xref>). The publicly available clinical, survival, CCNE1 amplification, and the CHAMP1 mRNA expression data of tumors, belonging to the Pan-Cancer group, were retrieved from the public cBioPortal (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cbioportal.org/" ext-link-type="uri">https://www.cbioportal.org/</ext-link>). These data are deidentified and publicly available. The corresponding patients were split into the high- and low-CHAMP1 groups by the median CHAMP1 expression. Survival analyses were performed in R, separately for tumors with and without CCNE1 amplification, to compare the overall survivals of the two CHAMP1 groups. The survival (version 3.8-3) R package was used to calculate the Kaplan&#8211;Meier curves, and to perform the log-rank test with chi-square-distribution <italic toggle="yes">P</italic> values. The median survivals were derived, and the Kaplan&#8211;Meier curves were visualized, using the survminer (version 0.5.0) R package. The hazard ratios were computed with the Cox proportional hazards regressions.</p></sec><sec id="s22"><title>Quantification and Statistical Analysis.</title><p>All data are presented as either SD or SEM as indicated in figure legends. Statistical significance was evaluated using Student&#8217;s <italic toggle="yes">t</italic> test for comparison of two groups and one-way analyses of variance (ANOVA) or the Mann&#8211;Whitney <italic toggle="yes">U</italic> test for comparison among multiple groups using, with analysis being performed using Graphpad Prism 9 and 10.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material position="float" content-type="local-data" orientation="portrait"><caption><p>Appendix 01 (PDF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pnas.2525144122.sapp.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack><p>We thank all members of the D&#8217;Andrea laboratory for their helpful suggestions and comments. This work was supported by grants from the US National Institutes of Health (R01HL052725), the Breast Cancer Research Foundation, the Ludwig Center at Harvard, the Smith Family Foundation, and the Innovations Research Fund of the Dana-Farber Cancer Institute (A.D.D.). This work was also supported by the Claudia Adams Barr Program in Innovative Basic Cancer Research (F.L. and A.S.) and by the David Liposarcoma Research Initiative via the Rossy Foundation Fund (Myriad Canada).</p><sec id="s24"><title>Author contributions</title><p>A.E., F.Y.Z., T.Z., R.R., A.S., and L.S. performed experiments; H.N. performed the computational analysis; F.L., S.M., R.A.G., and A.D.D. conceived the study; F.L., A.E., F.Y.Z., T.Z., R.R., H.N., A.S., L.S., S.M., R.A.G., and A.D.D. analyzed data; and F.L., S.M., R.A.G., and A.D.D. wrote the paper.</p></sec><sec sec-type="COI-statement" id="s25"><title>Competing interests</title><p>The authors declare no competing interest.</p></sec></ack><fn-group><fn id="fn3" fn-type="other"><p>Reviewers: C.J.B., University of Pittsburgh; and T.T.H., NYU Langone Health.</p></fn></fn-group><sec sec-type="data-availability" id="s23"><title>Data, Materials, and Software Availability</title><p content-type="flushleft">All study data are included in the article and/or <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pnas.org/lookup/doi/10.1073/pnas.2525144122#supplementary-materials" ext-link-type="uri"><italic toggle="yes">SI Appendix</italic></ext-link>.</p></sec><ref-list><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>L.</given-names><surname>Curti</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Campaner</surname></string-name></person-group>, <article-title>MYC-induced replicative stress: A double-edged sword for cancer development and treatment</article-title>. <source>Int. J. Mol. Sci.</source><volume><bold>22</bold></volume>, <elocation-id>6168</elocation-id> (<year>2021</year>), <pub-id pub-id-type="doi">10.3390/ijms22126168</pub-id>.<pub-id pub-id-type="pmid">34201047</pub-id><pub-id pub-id-type="pmcid">PMC8227504</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>Y. P.</given-names><surname>Kok</surname></string-name><etal/></person-group>, <article-title>Overexpression of cyclin E1 or Cdc25A leads to replication stress, mitotic aberrancies, and increased sensitivity to replication checkpoint inhibitors</article-title>. <source>Oncogenesis</source><volume><bold>9</bold></volume>, <fpage>88</fpage> (<year>2020</year>), <pub-id pub-id-type="doi">10.1038/s41389-020-00270-2</pub-id>.<pub-id pub-id-type="pmid">33028815</pub-id><pub-id pub-id-type="pmcid">PMC7542455</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>B.</given-names><surname>Benedict</surname></string-name><etal/></person-group>, <article-title>Loss of p53 suppresses replication-stress-induced DNA breakage in G1/S checkpoint deficient cells</article-title>. <source>elife</source><volume><bold>7</bold></volume>, <elocation-id>e37868</elocation-id> (<year>2018</year>), <pub-id pub-id-type="doi">10.7554/eLife.37868</pub-id>.<pub-id pub-id-type="pmid">30322449</pub-id><pub-id pub-id-type="pmcid">PMC6221544</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>S.</given-names><surname>Saxena</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zou</surname></string-name></person-group>, <article-title>Hallmarks of DNA replication stress</article-title>. <source>Mol. Cell</source><volume><bold>82</bold></volume>, <fpage>2298</fpage>&#8211;<lpage>2314</lpage> (<year>2022</year>), <pub-id pub-id-type="doi">10.1016/j.molcel.2022.05.004</pub-id>.<pub-id pub-id-type="pmid">35714587</pub-id><pub-id pub-id-type="pmcid">PMC9219557</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>A.</given-names><surname>Simoneau</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zou</surname></string-name></person-group>, <article-title>An extending ATR-CHK1 circuitry: The replication stress response and beyond</article-title>. <source>Curr. Opin. Genet. Dev.</source><volume><bold>71</bold></volume>, <fpage>92</fpage>&#8211;<lpage>98</lpage> (<year>2021</year>), <pub-id pub-id-type="doi">10.1016/j.gde.2021.07.003</pub-id>.<pub-id pub-id-type="pmid">34329853</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>L. M.</given-names><surname>Carson</surname></string-name>, <string-name name-style="western"><given-names>R. L.</given-names><surname>Flynn</surname></string-name></person-group>, <article-title>Highlighting vulnerabilities in the alternative lengthening of telomeres pathway</article-title>. <source>Curr. Opin. Pharmacol.</source><volume><bold>70</bold></volume>, <elocation-id>102380</elocation-id> (<year>2023</year>), <pub-id pub-id-type="doi">10.1016/j.coph.2023.102380</pub-id>.<pub-id pub-id-type="pmid">37149932</pub-id><pub-id pub-id-type="pmcid">PMC10247456</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>E. J.</given-names><surname>Sohn</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Goralsky</surname></string-name>, <string-name name-style="western"><given-names>J. W.</given-names><surname>Shay</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Min</surname></string-name></person-group>, <article-title>The molecular mechanisms and therapeutic prospects of Alternative Lengthening of Telomeres (ALT)</article-title>. <source>Cancers (Basel)</source><volume><bold>15</bold></volume>, <elocation-id>1945</elocation-id> (<year>2023</year>), <pub-id pub-id-type="doi">10.3390/cancers15071945</pub-id>.<pub-id pub-id-type="pmid">37046606</pub-id><pub-id pub-id-type="pmcid">PMC10093677</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>R. L.</given-names><surname>Flynn</surname></string-name><etal/></person-group>, <article-title>Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors</article-title>. <source>Science</source><volume><bold>347</bold></volume>, <fpage>273</fpage>&#8211;<lpage>277</lpage> (<year>2015</year>), <pub-id pub-id-type="doi">10.1126/science.1257216</pub-id>.<pub-id pub-id-type="pmid">25593184</pub-id><pub-id pub-id-type="pmcid">PMC4358324</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>D.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Hou</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Jia</surname></string-name></person-group>, <article-title>Regulation of replication stress in alternative lengthening of telomeres by Fanconi anaemia protein</article-title>. <source>Genes</source><volume><bold>13</bold></volume>, <elocation-id>180</elocation-id> (<year>2022</year>), <pub-id pub-id-type="doi">10.3390/genes13020180</pub-id>.<pub-id pub-id-type="pmid">35205225</pub-id><pub-id pub-id-type="pmcid">PMC8872277</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>R.</given-names><surname>Lu</surname></string-name><etal/></person-group>, <article-title>The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT)</article-title>. <source>Nat. Commun.</source><volume><bold>10</bold></volume>, <fpage>2252</fpage> (<year>2019</year>), <pub-id pub-id-type="doi">10.1038/s41467-019-10180-6</pub-id>.<pub-id pub-id-type="pmid">31138797</pub-id><pub-id pub-id-type="pmcid">PMC6538672</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>B.</given-names><surname>Silva</surname></string-name><etal/></person-group>, <article-title><italic toggle="yes">FANCM</italic> limits ALT activity by restricting telomeric replication stress induced by deregulated <italic toggle="yes">BLM</italic> and R-loops</article-title>. <source>Nat. Commun.</source><volume><bold>10</bold></volume>, <fpage>2253</fpage> (<year>2019</year>), <pub-id pub-id-type="doi">10.1038/s41467-019-10179-z</pub-id>.<pub-id pub-id-type="pmid">31138795</pub-id><pub-id pub-id-type="pmcid">PMC6538666</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>J. J.</given-names><surname>O&#8217;Rourke</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Bythell-Douglas</surname></string-name>, <string-name name-style="western"><given-names>E. A.</given-names><surname>Dunn</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>Deans</surname></string-name></person-group>, <article-title>ALT control, delete: FANCM as an anti-cancer target in alternative lengthening of telomeres</article-title>. <source>Nucleus</source><volume><bold>10</bold></volume>, <fpage>221</fpage>&#8211;<lpage>230</lpage> (<year>2019</year>), <pub-id pub-id-type="doi">10.1080/19491034.2019.1685246</pub-id>.<pub-id pub-id-type="pmid">31663812</pub-id><pub-id pub-id-type="pmcid">PMC6949022</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>F.</given-names><surname>Li</surname></string-name><etal/></person-group>, <article-title>CHAMP1 complex directs heterochromatin assembly and promotes homology-directed DNA repair</article-title>. <source>Nat. Commun.</source><volume><bold>16</bold></volume>, <fpage>1714</fpage> (<year>2025</year>), <pub-id pub-id-type="doi">10.1038/s41467-025-56834-6</pub-id>.<pub-id pub-id-type="pmid">39962076</pub-id><pub-id pub-id-type="pmcid">PMC11832927</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>T.</given-names><surname>Zhang</surname></string-name><etal/></person-group>, <article-title>Break-induced replication orchestrates resection-dependent template switching</article-title>. <source>Nature</source><volume><bold>619</bold></volume>, <fpage>201</fpage>&#8211;<lpage>208</lpage> (<year>2023</year>), <pub-id pub-id-type="doi">10.1038/s41586-023-06177-3</pub-id>.<pub-id pub-id-type="pmid">37316655</pub-id><pub-id pub-id-type="pmcid">PMC10937050</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>F.</given-names><surname>Li</surname></string-name><etal/></person-group>, <article-title>CHAMP1 binds to REV7/FANCV and promotes homologous recombination repair</article-title>. <source>Cell Rep.</source><volume><bold>40</bold></volume>, <elocation-id>111297</elocation-id> (<year>2022</year>), <pub-id pub-id-type="doi">10.1016/j.celrep.2022.111297</pub-id>.<pub-id pub-id-type="pmid">36044844</pub-id><pub-id pub-id-type="pmcid">PMC9472291</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>H.</given-names><surname>Fujita</surname></string-name><etal/></person-group>, <article-title>CHAMP1-POGZ counteracts the inhibitory effect of 53BP1 on homologous recombination and affects PARP inhibitor resistance</article-title>. <source>Oncogene</source><volume><bold>41</bold></volume>, <fpage>2706</fpage>&#8211;<lpage>2718</lpage> (<year>2022</year>), <pub-id pub-id-type="doi">10.1038/s41388-022-02299-6</pub-id>.<pub-id pub-id-type="pmid">35393543</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>H.</given-names><surname>Dev</surname></string-name><etal/></person-group>, <article-title>Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells</article-title>. <source>Nat. Cell Biol.</source><volume><bold>20</bold></volume>, <fpage>954</fpage>&#8211;<lpage>965</lpage> (<year>2018</year>), <pub-id pub-id-type="doi">10.1038/s41556-018-0140-1</pub-id>.<pub-id pub-id-type="pmid">30022119</pub-id><pub-id pub-id-type="pmcid">PMC6145444</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>H.</given-names><surname>Ghezraoui</surname></string-name><etal/></person-group>, <article-title>53BP1 cooperation with the REV7-shieldin complex underpins DNA structure-specific NHEJ</article-title>. <source>Nature</source><volume><bold>560</bold></volume>, <fpage>122</fpage>&#8211;<lpage>127</lpage> (<year>2018</year>), <pub-id pub-id-type="doi">10.1038/s41586-018-0362-1</pub-id>.<pub-id pub-id-type="pmid">30046110</pub-id><pub-id pub-id-type="pmcid">PMC6989217</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>R.</given-names><surname>Gupta</surname></string-name><etal/></person-group>, <article-title>DNA repair network analysis reveals Shieldin as a key regulator of NHEJ and PARP inhibitor sensitivity</article-title>. <source>Cell</source><volume><bold>173</bold></volume>, <fpage>972</fpage>&#8211;<lpage>988.e923</lpage> (<year>2018</year>), <pub-id pub-id-type="doi">10.1016/j.cell.2018.03.050</pub-id>.<pub-id pub-id-type="pmid">29656893</pub-id><pub-id pub-id-type="pmcid">PMC8108093</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>Z.</given-names><surname>Mirman</surname></string-name><etal/></person-group>, <article-title>53BP1-RIF1-shieldin counteracts DSB resection through CST- and Polalpha-dependent fill-in</article-title>. <source>Nature</source><volume><bold>560</bold></volume>, <fpage>112</fpage>&#8211;<lpage>116</lpage> (<year>2018</year>), <pub-id pub-id-type="doi">10.1038/s41586-018-0324-7</pub-id>.<pub-id pub-id-type="pmid">30022158</pub-id><pub-id pub-id-type="pmcid">PMC6072559</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>S. M.</given-names><surname>Noordermeer</surname></string-name><etal/></person-group>, <article-title>The shieldin complex mediates 53BP1-dependent DNA repair</article-title>. <source>Nature</source><volume><bold>560</bold></volume>, <fpage>117</fpage>&#8211;<lpage>121</lpage> (<year>2018</year>), <pub-id pub-id-type="doi">10.1038/s41586-018-0340-7</pub-id>.<pub-id pub-id-type="pmid">30022168</pub-id><pub-id pub-id-type="pmcid">PMC6141009</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>M.</given-names><surname>Garrity</surname></string-name><etal/></person-group>, <article-title>Neurodevelopmental phenotypes in individuals with pathogenic variants in CHAMP1</article-title>. <source>Cold Spring Harb. Mol. Case Stud.</source><volume><bold>7</bold></volume>, <elocation-id>a006092</elocation-id> (<year>2021</year>), <pub-id pub-id-type="doi">10.1101/mcs.a006092</pub-id>.<pub-id pub-id-type="pmid">34021018</pub-id><pub-id pub-id-type="pmcid">PMC8327885</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>M.</given-names><surname>Hempel</surname></string-name><etal/></person-group>, <article-title>De novo mutations in CHAMP1 cause intellectual disability with severe speech impairment</article-title>. <source>Am. J. Hum. Genet.</source><volume><bold>97</bold></volume>, <fpage>493</fpage>&#8211;<lpage>500</lpage> (<year>2015</year>), <pub-id pub-id-type="doi">10.1016/j.ajhg.2015.08.003</pub-id>.<pub-id pub-id-type="pmid">26340335</pub-id><pub-id pub-id-type="pmcid">PMC4564986</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>B.</given-names><surname>Isidor</surname></string-name><etal/></person-group>, <article-title>De novo truncating mutations in the kinetochore-microtubules attachment gene CHAMP1 cause syndromic intellectual disability</article-title>. <source>Hum. Mutat.</source><volume><bold>37</bold></volume>, <fpage>354</fpage>&#8211;<lpage>358</lpage> (<year>2016</year>), <pub-id pub-id-type="doi">10.1002/humu.22952</pub-id>.<pub-id pub-id-type="pmid">26751395</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>T.</given-names><surname>Levy</surname></string-name><etal/></person-group>, <article-title>CHAMP1 disorder is associated with a complex neurobehavioral phenotype including autism, ADHD, repetitive behaviors and sensory symptoms</article-title>. <source>Hum. Mol. Genet.</source><volume><bold>31</bold></volume>, <fpage>2582</fpage>&#8211;<lpage>2594</lpage> (<year>2022</year>), <pub-id pub-id-type="doi">10.1093/hmg/ddac018</pub-id>.<pub-id pub-id-type="pmid">35271727</pub-id><pub-id pub-id-type="pmcid">PMC9396938</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>A. J.</given-names><surname>Tanaka</surname></string-name><etal/></person-group>, <article-title>De novo pathogenic variants in CHAMP1 are associated with global developmental delay, intellectual disability, and dysmorphic facial features</article-title>. <source>Cold Spring Harb. Mol. Case Stud.</source><volume><bold>2</bold></volume>, <elocation-id>a000661</elocation-id> (<year>2016</year>), <pub-id pub-id-type="doi">10.1101/mcs.a000661</pub-id>.<pub-id pub-id-type="pmid">27148580</pub-id><pub-id pub-id-type="pmcid">PMC4849844</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>M. L.</given-names><surname>Dentici</surname></string-name><etal/></person-group>, <article-title>Expanding the phenotypic spectrum of truncating POGZ mutations: Association with CNS malformations, skeletal abnormalities, and distinctive facial dysmorphism</article-title>. <source>Am. J. Med. Genet. A.</source><volume><bold>173</bold></volume>, <fpage>1965</fpage>&#8211;<lpage>1969</lpage> (<year>2017</year>), <pub-id pub-id-type="doi">10.1002/ajmg.a.38255</pub-id>.<pub-id pub-id-type="pmid">28480548</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>J.</given-names><surname>Duan</surname></string-name><etal/></person-group>, <article-title>White-sutton syndrome and congenital heart disease: Case report and literature review</article-title>. <source>BMC Pediatr.</source><volume><bold>23</bold></volume>, <fpage>158</fpage> (<year>2023</year>), <pub-id pub-id-type="doi">10.1186/s12887-023-03972-9</pub-id>.<pub-id pub-id-type="pmid">37016333</pub-id><pub-id pub-id-type="pmcid">PMC10071667</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>A.</given-names><surname>Ferretti</surname></string-name><etal/></person-group>, <article-title>POGZ-related epilepsy: Case report and review of the literature</article-title>. <source>Am. J. Med. Genet. A.</source><volume><bold>179</bold></volume>, <fpage>1631</fpage>&#8211;<lpage>1636</lpage> (<year>2019</year>), <pub-id pub-id-type="doi">10.1002/ajmg.a.61206</pub-id>.<pub-id pub-id-type="pmid">31136090</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>R.</given-names><surname>Fukai</surname></string-name><etal/></person-group>, <article-title>A case of autism spectrum disorder arising from a <italic toggle="yes">de novo</italic> missense mutation in POGZ</article-title>. <source>J. Hum. Genet.</source><volume><bold>60</bold></volume>, <fpage>277</fpage>&#8211;<lpage>279</lpage> (<year>2015</year>), <pub-id pub-id-type="doi">10.1038/jhg.2015.13</pub-id>.<pub-id pub-id-type="pmid">25694107</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>K.</given-names><surname>Matsumura</surname></string-name><etal/></person-group>, <article-title>De novo <italic toggle="yes">POGZ</italic> mutations in sporadic autism disrupt the DNA-binding activity of <italic toggle="yes">POGZ</italic></article-title>. <source>J. Mol. Psychiatry</source><volume><bold>4</bold></volume>, <fpage>1</fpage> (<year>2016</year>), <pub-id pub-id-type="doi">10.1186/s40303-016-0016-x</pub-id>.<pub-id pub-id-type="pmid">27103995</pub-id><pub-id pub-id-type="pmcid">PMC4839133</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>B.</given-names><surname>Tan</surname></string-name><etal/></person-group>, <article-title>A novel de novo <italic toggle="yes">POGZ</italic> mutation in a patient with intellectual disability</article-title>. <source>J. Hum. Genet.</source><volume><bold>61</bold></volume>, <fpage>357</fpage>&#8211;<lpage>359</lpage> (<year>2016</year>), <pub-id pub-id-type="doi">10.1038/jhg.2015.156</pub-id>.<pub-id pub-id-type="pmid">26763879</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>Y.</given-names><surname>Ye</surname></string-name><etal/></person-group>, <article-title>De novo POGZ mutations are associated with neurodevelopmental disorders and microcephaly</article-title>. <source>Cold Spring Harb. Mol. Case Stud.</source><volume><bold>1</bold></volume>, <elocation-id>a000455</elocation-id> (<year>2015</year>), <pub-id pub-id-type="doi">10.1101/mcs.a000455</pub-id>.<pub-id pub-id-type="pmid">27148570</pub-id><pub-id pub-id-type="pmcid">PMC4850885</pub-id></mixed-citation></ref><ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>W.</given-names><surname>Zhao</surname></string-name><etal/></person-group>, <article-title><italic toggle="yes">POGZ</italic> de novo missense variants in neuropsychiatric disorders</article-title>. <source>Mol. Genet. Genomic Med.</source><volume><bold>7</bold></volume>, <elocation-id>e900</elocation-id> (<year>2019</year>), <pub-id pub-id-type="doi">10.1002/mgg3.900</pub-id>.<pub-id pub-id-type="pmid">31347273</pub-id><pub-id pub-id-type="pmcid">PMC6732319</pub-id></mixed-citation></ref><ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>W.</given-names><surname>Zhao</surname></string-name><etal/></person-group>, <article-title>Rare inherited missense variants of <italic toggle="yes">POGZ</italic> associate with autism risk and disrupt neuronal development</article-title>. <source>J. Genet. Genomics</source><volume><bold>46</bold></volume>, <fpage>247</fpage>&#8211;<lpage>257</lpage> (<year>2019</year>), <pub-id pub-id-type="doi">10.1016/j.jgg.2019.04.002</pub-id>.<pub-id pub-id-type="pmid">31196716</pub-id></mixed-citation></ref><ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>J. C.</given-names><surname>Saldivar</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Cortez</surname></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>Cimprich</surname></string-name></person-group>, <article-title>The essential kinase ATR: Ensuring faithful duplication of a challenging genome</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><volume><bold>18</bold></volume>, <fpage>622</fpage>&#8211;<lpage>636</lpage> (<year>2017</year>), <pub-id pub-id-type="doi">10.1038/nrm.2017.67</pub-id>.<pub-id pub-id-type="pmid">28811666</pub-id><pub-id pub-id-type="pmcid">PMC5796526</pub-id></mixed-citation></ref><ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>K. L.</given-names><surname>Chan</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Palmai-Pallag</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ying</surname></string-name>, <string-name name-style="western"><given-names>I. D.</given-names><surname>Hickson</surname></string-name></person-group>, <article-title>Replication stress induces sister-chromatid bridging at fragile site loci in mitosis</article-title>. <source>Nat. Cell Biol.</source><volume><bold>11</bold></volume>, <fpage>753</fpage>&#8211;<lpage>760</lpage> (<year>2009</year>), <pub-id pub-id-type="doi">10.1038/ncb1882</pub-id>.<pub-id pub-id-type="pmid">19465922</pub-id></mixed-citation></ref><ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>T.</given-names><surname>Wilhelm</surname></string-name><etal/></person-group>, <article-title>Mild replication stress causes chromosome mis-segregation via premature centriole disengagement</article-title>. <source>Nat. Commun.</source><volume><bold>10</bold></volume>, <fpage>3585</fpage> (<year>2019</year>), <pub-id pub-id-type="doi">10.1038/s41467-019-11584-0</pub-id>.<pub-id pub-id-type="pmid">31395887</pub-id><pub-id pub-id-type="pmcid">PMC6687892</pub-id></mixed-citation></ref><ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>S.</given-names><surname>Roy</surname></string-name>, <string-name name-style="western"><given-names>J. W.</given-names><surname>Luzwick</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Schlacher</surname></string-name></person-group>, <article-title>SIRF: Quantitative in situ analysis of protein interactions at DNA replication forks</article-title>. <source>J. Cell Biol.</source><volume><bold>217</bold></volume>, <fpage>1521</fpage>&#8211;<lpage>1536</lpage> (<year>2018</year>), <pub-id pub-id-type="doi">10.1083/jcb.201709121</pub-id>.<pub-id pub-id-type="pmid">29475976</pub-id><pub-id pub-id-type="pmcid">PMC5881507</pub-id></mixed-citation></ref><ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>S.</given-names><surname>Roy</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Schlacher</surname></string-name></person-group>, <article-title>SIRF: A single-cell assay for in situ protein interaction with nascent DNA replication forks</article-title>. <source>Bio-protocol</source><volume><bold>9</bold></volume>, <elocation-id>e3377</elocation-id> (<year>2019</year>), <pub-id pub-id-type="doi">10.21769/BioProtoc.3377</pub-id>.<pub-id pub-id-type="pmid">33654873</pub-id><pub-id pub-id-type="pmcid">PMC7854004</pub-id></mixed-citation></ref><ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>A.</given-names><surname>Costa</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Chowdhury</surname></string-name>, <string-name name-style="western"><given-names>G. I.</given-names><surname>Shapiro</surname></string-name>, <string-name name-style="western"><given-names>A. D.</given-names><surname>D&#8217;Andrea</surname></string-name>, <string-name name-style="western"><given-names>P. A.</given-names><surname>Konstantinopoulos</surname></string-name></person-group>, <article-title>Targeting replication stress in cancer therapy</article-title>. <source>Nat. Rev. Drug Discov.</source><volume><bold>22</bold></volume>, <fpage>38</fpage>&#8211;<lpage>58</lpage> (<year>2023</year>), <pub-id pub-id-type="doi">10.1038/s41573-022-00558-5</pub-id>.<pub-id pub-id-type="pmid">36202931</pub-id><pub-id pub-id-type="pmcid">PMC11132912</pub-id></mixed-citation></ref><ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>M.</given-names><surname>Daza-Martin</surname></string-name><etal/></person-group>, <article-title>Isomerization of BRCA1-BARD1 promotes replication fork protection</article-title>. <source>Nature</source><volume><bold>571</bold></volume>, <fpage>521</fpage>&#8211;<lpage>527</lpage> (<year>2019</year>), <pub-id pub-id-type="doi">10.1038/s41586-019-1363-4</pub-id>.<pub-id pub-id-type="pmid">31270457</pub-id></mixed-citation></ref><ref id="r43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>V.</given-names><surname>Gaggioli</surname></string-name><etal/></person-group>, <article-title>Dynamic de novo heterochromatin assembly and disassembly at replication forks ensures fork stability</article-title>. <source>Nat. Cell Biol.</source><volume><bold>25</bold></volume>, <fpage>1017</fpage>&#8211;<lpage>1032</lpage> (<year>2023</year>), <pub-id pub-id-type="doi">10.1038/s41556-023-01167-z</pub-id>.<pub-id pub-id-type="pmid">37414849</pub-id><pub-id pub-id-type="pmcid">PMC10344782</pub-id></mixed-citation></ref><ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>N. W.</given-names><surname>Cho</surname></string-name>, <string-name name-style="western"><given-names>R. L.</given-names><surname>Dilley</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Lampson</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Greenberg</surname></string-name></person-group>, <article-title>Interchromosomal homology searches drive directional ALT telomere movement and synapsis</article-title>. <source>Cell</source><volume><bold>159</bold></volume>, <fpage>108</fpage>&#8211;<lpage>121</lpage> (<year>2014</year>), <pub-id pub-id-type="doi">10.1016/j.cell.2014.08.030</pub-id>.<pub-id pub-id-type="pmid">25259924</pub-id><pub-id pub-id-type="pmcid">PMC4177039</pub-id></mixed-citation></ref><ref id="r45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>R.</given-names><surname>Lu</surname></string-name>, <string-name name-style="western"><given-names>H. A.</given-names><surname>Pickett</surname></string-name></person-group>, <article-title>Telomeric replication stress: The beginning and the end for alternative lengthening of telomeres cancers</article-title>. <source>Open Biol.</source><volume><bold>12</bold></volume>, <elocation-id>220011</elocation-id> (<year>2022</year>), <pub-id pub-id-type="doi">10.1098/rsob.220011</pub-id>.<pub-id pub-id-type="pmid">35259951</pub-id><pub-id pub-id-type="pmcid">PMC8905155</pub-id></mixed-citation></ref><ref id="r46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>M. D.</given-names><surname>Cubiles</surname></string-name><etal/></person-group>, <article-title>Epigenetic features of human telomeres</article-title>. <source>Nucleic Acids Res.</source><volume><bold>46</bold></volume>, <fpage>2347</fpage>&#8211;<lpage>2355</lpage> (<year>2018</year>), <pub-id pub-id-type="doi">10.1093/nar/gky006</pub-id>.<pub-id pub-id-type="pmid">29361030</pub-id><pub-id pub-id-type="pmcid">PMC5861411</pub-id></mixed-citation></ref><ref id="r47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>M.</given-names><surname>Gauchier</surname></string-name><etal/></person-group>, <article-title>SETDB1-dependent heterochromatin stimulates alternative lengthening of telomeres</article-title>. <source>Sci. Adv.</source><volume><bold>5</bold></volume>, <elocation-id>eaav3673</elocation-id> (<year>2019</year>), <pub-id pub-id-type="doi">10.1126/sciadv.aav3673</pub-id>.<pub-id pub-id-type="pmid">31086817</pub-id><pub-id pub-id-type="pmcid">PMC6506250</pub-id></mixed-citation></ref><ref id="r48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>G.</given-names><surname>Shi</surname></string-name><etal/></person-group>, <article-title>A critical role of telomere chromatin compaction in ALT tumor cell growth</article-title>. <source>Nucleic Acids Res.</source><volume><bold>48</bold></volume>, <fpage>6019</fpage>&#8211;<lpage>6031</lpage> (<year>2020</year>), <pub-id pub-id-type="doi">10.1093/nar/gkaa224</pub-id>.<pub-id pub-id-type="pmid">32379321</pub-id><pub-id pub-id-type="pmcid">PMC7293046</pub-id></mixed-citation></ref><ref id="r49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>M.</given-names><surname>Udugama</surname></string-name><etal/></person-group>, <article-title>Mutations inhibiting KDM4B drive ALT activation in ATRX-mutated glioblastomas</article-title>. <source>Nat. Commun.</source><volume><bold>12</bold></volume>, <fpage>2584</fpage> (<year>2021</year>), <pub-id pub-id-type="doi">10.1038/s41467-021-22543-z</pub-id>.<pub-id pub-id-type="pmid">33972520</pub-id><pub-id pub-id-type="pmcid">PMC8110556</pub-id></mixed-citation></ref><ref id="r50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>J.</given-names><surname>Fielden</surname></string-name><etal/></person-group>, <article-title>Comprehensive interrogation of synthetic lethality in the DNA damage response</article-title>. <source>Nature</source><volume><bold>640</bold></volume>, <fpage>1093</fpage>&#8211;<lpage>1102</lpage> (<year>2025</year>), <pub-id pub-id-type="doi">10.1038/s41586-025-08815-4</pub-id>.<pub-id pub-id-type="pmid">40205037</pub-id><pub-id pub-id-type="pmcid">PMC12018271</pub-id></mixed-citation></ref><ref id="r51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>A.</given-names><surname>Sfeir</surname></string-name><etal/></person-group>, <article-title>Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication</article-title>. <source>Cell</source><volume><bold>138</bold></volume>, <fpage>90</fpage>&#8211;<lpage>103</lpage> (<year>2009</year>), <pub-id pub-id-type="doi">10.1016/j.cell.2009.06.021</pub-id>.<pub-id pub-id-type="pmid">19596237</pub-id><pub-id pub-id-type="pmcid">PMC2723738</pub-id></mixed-citation></ref><ref id="r52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>B.</given-names><surname>Domingues-Silva</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Silva</surname></string-name>, <string-name name-style="western"><given-names>C. M.</given-names><surname>Azzalin</surname></string-name></person-group>, <article-title>ALTernative functions for human FANCM at telomeres</article-title>. <source>Front. Mol. Biosci.</source><volume><bold>6</bold></volume>, <fpage>84</fpage> (<year>2019</year>), <pub-id pub-id-type="doi">10.3389/fmolb.2019.00084</pub-id>.<pub-id pub-id-type="pmid">31552268</pub-id><pub-id pub-id-type="pmcid">PMC6743340</pub-id></mixed-citation></ref><ref id="r53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>X.</given-names><surname>Pan</surname></string-name><etal/></person-group>, <article-title>FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume><bold>114</bold></volume>, <fpage>E5940</fpage>&#8211;<lpage>E5949</lpage> (<year>2017</year>), <pub-id pub-id-type="doi">10.1073/pnas.1708065114</pub-id>.<pub-id pub-id-type="pmid">28673972</pub-id><pub-id pub-id-type="pmcid">PMC5530707</pub-id></mixed-citation></ref><ref id="r54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>R.</given-names><surname>Ceccaldi</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Sarangi</surname></string-name>, <string-name name-style="western"><given-names>A. D.</given-names><surname>D&#8217;Andrea</surname></string-name></person-group>, <article-title>The Fanconi anaemia pathway: New players and new functions</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><volume><bold>17</bold></volume>, <fpage>337</fpage>&#8211;<lpage>349</lpage> (<year>2016</year>), <pub-id pub-id-type="doi">10.1038/nrm.2016.48</pub-id>.<pub-id pub-id-type="pmid">27145721</pub-id></mixed-citation></ref><ref id="r55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>R.</given-names><surname>Ravindranathan</surname></string-name><etal/></person-group>, <article-title>PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume><bold>121</bold></volume>, <elocation-id>e2413954121</elocation-id> (<year>2024</year>), <pub-id pub-id-type="doi">10.1073/pnas.2413954121</pub-id>.<pub-id pub-id-type="pmid">39546575</pub-id><pub-id pub-id-type="pmcid">PMC11588084</pub-id></mixed-citation></ref><ref id="r56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>F.</given-names><surname>Li</surname></string-name><etal/></person-group>, <article-title>The <italic toggle="yes">BUB3-BUB1</italic> complex promotes telomere DNA replication</article-title>. <source>Mol. Cell</source><volume><bold>70</bold></volume>, <fpage>395</fpage>&#8211;<lpage>407.e394</lpage> (<year>2018</year>), <pub-id pub-id-type="doi">10.1016/j.molcel.2018.03.032</pub-id>.<pub-id pub-id-type="pmid">29727616</pub-id><pub-id pub-id-type="pmcid">PMC5982595</pub-id></mixed-citation></ref><ref id="r57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>F.</given-names><surname>Li</surname></string-name><etal/></person-group>, <article-title>Chk1 inhibitor blocks phosphorylation of FAM122A and promotes replication stress</article-title>. <source>Mol. Cell</source><volume><bold>80</bold></volume>, <fpage>410</fpage>&#8211;<lpage>422.e416</lpage> (<year>2020</year>), <pub-id pub-id-type="doi">10.1016/j.molcel.2020.10.008</pub-id>.<pub-id pub-id-type="pmid">33108758</pub-id><pub-id pub-id-type="pmcid">PMC7761918</pub-id></mixed-citation></ref><ref id="r58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>M.</given-names><surname>Ghandi</surname></string-name><etal/></person-group>, <article-title>Next-generation characterization of the cancer cell line encyclopedia</article-title>. <source>Nature</source><volume><bold>569</bold></volume>, <fpage>503</fpage>&#8211;<lpage>508</lpage> (<year>2019</year>), <pub-id pub-id-type="doi">10.1038/s41586-019-1186-3</pub-id>.<pub-id pub-id-type="pmid">31068700</pub-id><pub-id pub-id-type="pmcid">PMC6697103</pub-id></mixed-citation></ref><ref id="r59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>M. E.</given-names><surname>Ritchie</surname></string-name><etal/></person-group>, <article-title>Limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>. <source>Nucleic Acids Res.</source><volume><bold>43</bold></volume>, <elocation-id>e47</elocation-id> (<year>2015</year>), <pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id>.<pub-id pub-id-type="pmid">25605792</pub-id><pub-id pub-id-type="pmcid">PMC4402510</pub-id></mixed-citation></ref><ref id="r60"><label>60</label><mixed-citation publication-type="journal"><collab>Cancer Genome Atlas Research</collab><etal/>, <article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title>. <source>Nat. Genet.</source><volume><bold>45</bold></volume>, <fpage>1113</fpage>&#8211;<lpage>1120</lpage> (<year>2013</year>), <pub-id pub-id-type="doi">10.1038/ng.2764</pub-id>.<pub-id pub-id-type="pmid">24071849</pub-id><pub-id pub-id-type="pmcid">PMC3919969</pub-id></mixed-citation></ref></ref-list><sec sec-type="supplementary-material" id="s26"><title>Supporting Information</title></sec></back></article></pmc-articleset>